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ABSTRACT
HOT-MELT MIXING OF PARTIALLY MISCIBLE ACTIVE
PHARMACEUTICAL INGREDIENT-POLYMER MIXTURES
by
Min Yang
Solid dispersion/solution processes for producing pharmaceutical oral dosages such as
hot-met extrusion (HME) have received increasing attention by industry and academe
because they can enhance drugs’ solubility and even bioavailability to a great extent by
converting drugs from crystalline to amorphous form. HME can be carried out at two
process temperature regimes: one where Tprocess > Tm of the drug and the Tg of the
polymer (or the Tm for the case of semi-crystalline polymers); the other at Tm > Tprocess >
Tg (Tm for the case of semi-crystalline polymer). Processing below the drug’s melting
point in the second case has the advantage of reducing potential for degradation.
Broader applications of HME are often limited by two technical challenges. One
is that the active pharmaceutical ingredient (API) or the polymer may degrade at the
elevated temperatures during extrusion processing. To avoid this problem and yet obtain
a well-mixed solid dispersion/solution, HME needs to be carried out in an optimal
processing window, where the temperature is kept safely below the degradation
temperature but is high enough to enhance API’s dissolution in the polymer. Another
challenge is the possible physical instability of the extrudate during its shelf life. The
API’s solubility is decreased significantly once the temperature is dropped from the HME
processing temperature to room temperature. As a result, the drug may recrystallize from
the polymeric matrix. It is rather challenging to experimentally determine the API’s
solubility in the polymer and there are only few published articles in this area. In this

dissertation, solid dispersions of a model drug acetaminophen (APAP) and a
pharmaceutical grade polymer poly(ethylene oxide) (PEO) were prepared by using hotmelt mixing (HMM), a process closely related to HME. APAP’s solubility in PEO at
HME processing temperature was measured utilizing a novel rheological characterization
technique, hot-stage microscopy and differential scanning calorimetry (DSC). The results
from the three methods were consistent and the solubility was found to increase from
14% at 80 ºC to 41% at 140 ºC. A “phase diagram” was constructed based on the
experimental data and could be explored to design the HME process and formulation.
The apparent drug solubility at room temperature was estimated to be less than
10% via glass transition temperature (Tg) measurements using DSC and dynamic
mechanical thermal analysis (DMTA), scanning electron microscopy (SEM), and X-ray
diffraction (XRD). A model using the Flory-Huggins interaction parameter χ estimated
from the “phase diagram” was utilized to predict the room temperature solubility. The
drug’s solubility in the amorphous portion of PEO was estimated to be 11.7% at 300 K.
Since PEO is a semi-crystalline polymer with crystallinity of about 80%, the actual
solubility is around 2.3%, consistent with apparent solubility estimation.
A new method to determine APAP’s solubility at temperatures below the PEO’s
melting temperature was developed by observing the number of spherulitic nuclei,
growth rate and the “quality” of the spherulites under polarized optical microscopy
(POM). At 30 oC, the solubility was determined to be less than 1%, while at 50 oC the
solubility was 10%. The nucleation constant Kg, fold surface free energy σe and work of
chain folding q were calculated using the Hoffman-Lauritzen (HL) theory and it was
found that the chain folding of PEO became more difficult in the presence of APAP.
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CHAPTER 1
INTRODUCTION

1.1 Background Information
One of the major challenges for the pharmaceutical industry is that more than 40% of
marketed drugs are poorly water soluble[1] while the percentage of insoluble newly
developed chemical entities in pharmaceutical chemical laboratories is up to 60% of the
total.[2] As a result, solid dispersion technologies such as hot-met extrusion (HME) and
spray drying have become more popular because they can enhance the drugs’ solubility
and even bioavailability to a great extent by converting drugs from crystalline to
amorphous solution form.[3-5] An example of solubility enhancement is given in Figure
1.1, which shows the improvement of piroxicam dissolution rate after the spray-drying
process.[6] Plasma concentration of a drug substance in beagle dogs demonstrates
significant increase after hot-melt extrusion process (Figure 1.2).[7]

Figure 1.1 Dissolution profiles of (a) Piroxicam, (d) physical mixtures of piroxicam and
PVP K25 (1:4), (e) spray-dried solid dispersion of piroxicam and PVP K25 (1:4).[6]

1

(mg/ml)

2

Figure 1.2 Mean plasma concentrations in dogs (n=4) after oral administration of 50 mg
capsules. The samples from top to bottom are 20% melt-extruded drug-PVP K30 solid
dispersion, 30% melt-extruded drug-PVP K30 solid dispersion and 20% crystalline drug
triturated with 80% poloxamer 188 that served as the control.[7]
Chiou and Riegelman have defined solid dispersion as “a dispersion of one or
more active ingredients in an inert carrier at the solid state, prepared by the melting, the
solvent or the melting solvent method”.[8] Formulation of poorly soluble compounds as
solid dispersions might lead to particle size reduction, improved wetting, reduced
agglomeration, changes in the physical state of the drug and desirably dispersion on a
molecular level, according to the physical state of the solid dispersion. Nowadays, the
term solid dispersion is mostly linked to glass solutions of poorly soluble compounds,
using amorphous carriers with high glass transition temperatures. There are a large
variety of pharmaceutically approved polymers available for solid dispersion purpose,
including polyvinylpyrrolidone (PVP)[9,
vinylacetate) (PVP/VA),[11,

12]

10]

polyethylene

and its co-polymers poly(ethylene-cooxide (PEO),[13,

methylcellulose acetate succinate (HPMCAS),[15,

16]

14]

hydroxypropyl

hydroxypropyl methylcellulose

(HPMC),[17] acrylates[18, 19] etc. A list of carriers used for hot-melt extrusion dosage forms
was summarized by Crowley et al. in the review paper (Table 1.1).[20]

3
Table 1.1 Carriers Used to Prepare Hot-melt Extrusion Dosage Forms[20]
Chemical Name
Ammonio methacrylate copolymer
Poly(dimethylaminoethylmethacrylateco-methacrylic esters)
Poly(methyl acrylate-co-methyl
methacrylate-co-methacrylic acid)
Poly(methacrylic acid-co-methyl
methacrylate) 1:2
Hydroxypropyl cellulose
Ethyl cellulose
Cellulose acetate butyrate
Cellulose Acetate Phthalate
Poly(ethylene oxide)
Poly(ethylene glycol)
Poly(vinyl pyrrolidone)
Poly(vinyl acetate)
Hydroxypropyl methylcellulose phthalate
Polyvinylpyrrolidone-co-vinyl acetate
Hydroxypropyl Methylcellulose
Hydroxypropyl Methylcellulose Acetate
Succinate
Poly(lactide-co-glycolide)
Polyvinyl Alcohol
Chitosan Lactate
Pectin
Carbomer
Polycarbophil
Poly(ethylene-co-vinyl acetate)
Polyethylene
Poly(vinyl acetate-co-methacrylic acid)
Epoxy resin containing secondary amine
Polycaprolactone
Carnauba Wax
Ethylene-vinyl acetate copolymer
Glyceryl Palmitostearate
Hydrogenated Castor & Soybean Oil
Microcrystalline Wax
Corn Starch
Maltodextrin
Pregelatinized Starch
Isomalt
Potato Starch
Citric Acid
Sodium Bicarbonate
Methacrylic acid copolymer type C
Chitosan
Xanthan gum
Agar
Povidone
Lactose
Microcrystalline cellulose
Dibasic calcium phophate

Trade Name
Eudragit® RS/RL
Eudragit® E

Tg (oC)
64
50

Tm (oC)
-

Eudragit® 4135F

48

-

Eudragit® S

160

-

Klucel®
Ethocel®
CAB 381-0.5
Polyox® WSR
Carbowax®
Kollidon®
Sentry® plus
Kollidon® VA64
Methocel®
Aqoat-AS®

130
133
125
165
-67
-20
168
35-40
137
175
-

157
192
65-80
37-63
150
-

PLGA
Elvanol®
Sea-Cure®
Obipektin®
Carbopol® 974P
Noveon® AA-1
Elvax® 40W
CIBA-I
CIBA HI
Evatane®
Precirol® ATO 5
Sterotex® K
Lunacera®Paracera®
Palatinit®
Eudragit® L100-55
Plasdone® S-30
Avicel® PH 101
Emcompress®

-36
-125
80-100
203
-

45
140
84-145
82-85
52-55
145-150
153
104.4
201
-
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Recently, some new solid dispersion formulations have entered the market (Table
1.2): Kaletra (Abbott), Intelence (Tibotec), Certican (Novartis), Isoptin SR-E (Abbott),
Nivadil, Prograf (Fujisawa Pharmaceutical Co., Ltd) and Rezulin (Sankyo). All of these
new formulations utilize amorphous polymers as a carrier. A particular type of solid
dispersion is solid solution, where the API is dispersed on a molecular level in the
amorphous polymer.
Table 1.2 Examples of Commercially Available Solid Dispersions[21]
Brand Name
Gris-PEG
Cesamet
Kaletra
Sporanox
Intelence
Certican
Isoptin SR-E

Manufacturer
Pedinol Pharmacal Inc.
Valeant Pharmaceuticals
Abbott
Jassen Pharmaceutica
Tibotec
Novartis
Abbott
Fujisawa Pharmaceutical Co.,
Nivadil
Ltd
Fujisawa Pharmaceutical Co.,
Prograf
Ltd
Developed by Sankyo,
Rezulin
manufactured by Parke-Davis
division of Warner-Lambert
HPC, hydroxypropyl cellulose

Drug
Griseofulvin
Nabilone
Lopinavir, ritonavir
Itraconazole
Etravirin
Everolimus
Verapamil

Carrier
PEG6000
PVP
PVPVA (Copovidone)
HPMC
HPMC
HPMC
HPC/HPMC

Nivaldipine

HPMC

Tacrolimus

HPMC

Troglitazone

PVP

Granulator

Drug
dissolution

Polymer
melting

Feeding

Figure 1.3 Schematic diagram of twin-screw extrusion followed by granulation.[22]
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1.2 Mixing, Processing Temperature and Additives
Hot-melt extrusion (HME) is a process that involves mixing an active pharmaceutical
ingredient (API) particulate with a molten, water soluble polymeric excipient in
processing machines with one or more rotating screws. Figure 1.3 is a schematic diagram
of twin-screw extrusion. As compared to spray drying (Figure 1.4), HME has the
advantage of being continuous, solvent free, and easy to scale up. There are basically two
laminar flow mixing mechanisms in the extrusion process.[23] The first is dispersive
mixing, which involves the reduction of the size of a component having cohesive
character, within the continuous molten excipient phase. The component in HME may be
solid agglomerate if the processing temperature is below the melting point of the API, or
a dispersed liquid phase if the processing temperature is above the melting point of the
API. The cohesive character of the agglomerate is due to van der Waals forces between
the particles of the agglomerate, to the surface tension and elastic properties of the liquid
droplets, and to the surface tension of the gaseous bubbles. The second is distributive
mixing of components through flow, which stretches the interfacial area elements
between the components lacking a cohesive character and distributes them throughout the
volume. In distributive mixing, one not only needs to stretch the interfacial area, but also
to reorient it for effective mixing, as well as to randomize the interfacial elements
throughout the volume. The mechanisms of mixing of miscible and immiscible liquids
are depicted in Figure 1.5, and that of hard solid agglomerates with liquids in Figure 1.6.
In the former, elongational and shear stretching is the dominant mechanism, while in the
latter, shear stress dominates.
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Figure 1.4 Schematic diagram of a spray-drying process.[24]

Figure 1.5 Schematic representation of (a) laminar distributive mixing where the
miscible blob is stretched and deformed and distributed throughout the volume; (b) shows
the same process as (a) but with an immiscible liquid where the stretching leads to a
breakup process.[23]

7

Figure 1.6 Dispersive mixing of hard solid agglomerates with liquids that, after breakup,
are distributed throughout the volume.[23]
As mentioned above, the HME process can be conducted in two temperature
regimes: one where Tprocess > Tm of the drug and the Tg of the polymer (or the Tm of the
polymer for the case of semi-crystalline polymers); the other is Tm > Tprocess > Tg (or the
Tm of the polymer for the case of semi-crystalline polymers). The first case is illustrated
as Figure 1.5 and the second case is illustrated in more details as Figure 1.7. After the
drug and polymer particles are fed into an extruder or a batch mixer, the polymer starts to
melt due to the conductive heat from the barrel, and the frictional and plastic energy
dissipation, resulting in a suspension with drug particles.[19] If the drug exhibits enhanced
solubility in the water soluble polymeric excipient at the elevated processing temperature
of the HME process, then the suspended API crystals will begin to dissolve. A dissolved
liquid API layer is formed at the surface of the crystalline API. That layer is wiped away
by the laminar flow of the HME process, promoting faster dissolution as the old polymer
is replaced by fresh polymer melt. The drug molecules diffuse into the polymer melt via
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the boundary layer, and the size of the suspended particles diminishes until the particles
dissolved completely.

Figure 1.7 Schematic representation of the morphological changes of the drug and
polymer system in the solution formation process.[19]
There are many literature papers that used the first case processing temperatures
(Tprocess > Tm and Tg).[25-29] The four heating zones in the twin-screw extruder that
Patterson et al. used for carbamazepine (Tm of 190 oC) and PVP/VA 64 (Tg of 107 oC) or
PVP/VA 37 (Tg of 55 oC) (1:2 w/w) are 80-100 oC (throat), 188 oC, 185 oC and 185 oC.[30]
They used the zone temperatures 80-100 oC, 167 oC, 162 oC, 162 oC for dipyridamole (Tm
of 163 oC) and polymers. All products were extruded at approximately 10 rpm. Qi et al.
extruded felodipine (Tm of 145 oC) with Eudragit® E PO (Tg of 50 oC) at 160 oC and screw
speed of 100 rpm.[31] Generally speaking, the risk of degradation is higher in the first case
considering that many APIs have very high Tm. Processing below the APIs’ melting
temperatures in the second case above has the obvious advantage of reducing the
potential for degradation. Albers et al. extruded celecoxib (Tm of 162 oC) with Eudragit®
E PO (1:1 w/w) and found that the extrudates changed from opaque to transparent when
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the processing temperature increased from 152 to 157 oC, indicating the complete
dissolution of crystalline drug at higher processing temperature.[18] Nevertheless, 157 oC
was still 5 oC below the drug’s melting point. Besides, one could lower the temperature
even more for smaller drug loading samples. DiNunzio et al. were able to achieve
amorphous dispersion of hydrocortisone (Tm of 218 oC) in PVP/VA 64 (1:9 w/w) at the
extrusion temperature of 160 oC.[12] Qi et al. extruded acetaminophen (Tm of 170 oC) with
Eudragit® E PO at 140 oC with the speed of 200 rpm.[32] The extrudate strands produced
containing 10% of API were clear while the strands produced containing 20% were
opaque. When Tprocess < Tm of the drug, drug’s solubility at that temperature determines if
one can achieve a miscible melt-mixed product. The solubility topic will be discussed in
more details below.
Sometimes it is unavoidable to use plasticizers in order to reduce the Tg of a
polymer (if Tdegradation < Tg), and therefore reduce the extrusion processing temperatures.
Plasticizers also lower the melt viscosity and thus, lower the shear forces needed to
extrude a polymer, thereby improving the process of certain high molecular weight (high
viscosity) polymers.[33,

34]

Plasticization of the polymer is generally attributed to the

intermolecular secondary forces between the plasticizer and the polymer. The free
volume between polymer chains is increased by plasticizers, which leads to Tg and melt
viscosity reduction. Plasticizers used for pharmaceutical dosage forms must have good
stability, polymer-plasticizer compatibility and permanence, avoiding shelf life
migration.[20] Triethyl citrate (TEC),[35-37] and low molecular weight polyethylene
glycols[34,

38, 39]

are the common plasticizers used for pharmaceutical extrusion. The

physical and mechanical properties and drug release rate of pharmaceutical dosage forms
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are dependent on the permanence of the plasticizers. Permanence of a plasticizer during
processing and storage is very important and the evaporation of highly volatile
plasticizers from the dosage form during storage has been studied and reported. Repka
and McGinity demonstrated that the amount of plasticizer remaining in hot-melt extruded
films over time was a function of the plasticizer type and storage conditions.[34] In
transdermal films, the addition of a plasticizer can improve the film’s flexibility.[34] It is
interesting that several drug substances have been reported to function as plasticizers in
the hot-melt extrusion process.[40-42] CO2 has been injected into the extruder at
supercritical pressures, dissolved in the melt, and used as a temporary plasticizer in the
HME.[43] At the die of the extruder, expansion occurs to atmospheric pressure which
results in a transformation of CO2 to the gaseous phase. As a consequence, CO2 escapes
from the extrudate and is not present in the final product.
The elevated temperatures needed to process unplasticized or plasticized
polymers may lead to polymer degradation. The stability of polymers that are susceptible
to degradation can be improved with the addition of antioxidants, acid receptors and or
light absorbers during HME. One manufacturer of these materials recommends the
incorporation of an antioxidant into formulations containing low molecular weight
hydroxypropylcellulose.[44] Similarly, poly(ethylene oxide) has been reported to be
protected from free radical and oxidative degradation by the incorporation of one or more
antioxidants.[45] This will be discussed in greater detail in the next chapter on material
properties.
Antioxidants are classified as preventive antioxidants or chain-breaking
antioxidants based upon their mechanism. Preventive antioxidants include materials that
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act to prevent initiation of free radical chain reactions. Reducing agents, such as ascorbic
acid, are able to interfere with autoxidation in a preventive manner since they
preferentially undergo oxidation. The preferential oxidation of reducing agents protects
drugs and polymers from attack by oxygen molecules. These antioxidants are sometimes
referred to as oxygen scavengers. They are most effective when used in a closed system
where oxygen cannot be replaced once it is consumed. Chelating agents such as edetate
disodium (EDTA) and citric acid are another type of preventive antioxidant that decrease
the rate of free radical formation by forming a stable complex with metal ions that
catalyze these reduction reactions.[20]
Hindered phenols and aromatic amines are the two major groups of chain
breaking antioxidants that inhibit free radical chain reactions. Commonly used
antioxidants such as butylated hydroxyanisole, butylated hydroxytoluene and vitamin E
are hindered phenols. Because the O-H bonds of phenols and the N-H bonds of aromatic
amines are very weak, the rate of oxidation is generally higher with the antioxidant than
with the polymer. Other materials have been used to facilitate HME processing. Waxy
materials like glyceryl monostearate have been reported to function as a thermal lubricant
during hot-melt processing. Vitamin E TPGS has been reported to plasticize polymers
and enhance drug absorption.[45, 46]
The efficiency of the HME process does not depend only on the API and polymer
material properties mentioned above. It also depends on extruder design variables and
process variables, such as screw rpm, barrel set temperature profiles, residence time
distribution and flow rate. Researchers have used very low rotating speeds such as 10
rpm[30] to high speeds such as 200 rpm[32], all of which worked well for the particular
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materials processed. Qian et al. extruded a model drug (Tm of 160 oC) with PVP/VA 64
(Tg of 107 oC) (4:6 w/w) at 150 oC, and they compared the speed between 50 and 225
rpm.[47] A micro phase-separation of the drug and polymer was observed under the
Raman mapping after the samples were stored for 2 months (Figure 1.8). Liu et al. meltmixed indomethacin (Tm of 163 oC) and Eudagit® E PO (Tg of 53 oC) (3:7 w/w) at
different rotating speed and temperatures.[19] It was found that at 140 oC, indomethacin
was able to totally dissolve in E PO at 20 rpm. At 100 and 110 oC, however, a screw
speed of 100 rpm was needed for a full dissolution. In the work of this dissertation, only
the results from 50 rpm are presented. The reason is that when Tprocess > Tmmix (drug’s
dissolution temperature, details will be discussed in Chapter 3.1), melt-mixed samples
were transparent, indicating the drug was well-mixed and completely dissolved in the
polymer. The other reason why only one rotating speed was used in this dissertation is
that for the particular API-excipient system, acetaminophen and poly(ethylene oxide),
material properties are the main determining factor on miscibility and shelf-life stability.
The processing conditions are far less important compared to the thermodynamics of
mixing and therefore, the focus is placed on the latter.
In practice, the mean residence time in the twin-screw extruder ranges from one to
10 minutes.[48-50] It is desirable to shorten the residence time during processing to reduce
the risk of degradation.[12] A long residence time of 10 minutes was used in this work for
sample preparation to secure a well-mixed, homogeneous and dissolved state.
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Figure 1.8 Raman mapping of drug-PVP/VA processed at (a) 50 rpm; and (b) 225 rpm.
Red color represents higher concentration of the model drug.[47]

1.3 Challenges of HME
Solid dispersions/solutions with a wide range of API release profiles can be manufactured
via HME, considering the richness of the polymer chemistry and the powerful mixing and
shaping capability of the extrusion process. A new graft copolymer Soluplus® has been
developed specifically for the purpose of pharmaceutical HME.[51] Besides instant-release
oral formulations,[10, 18, 19, 52, 53] HME-prepared solid dispersions/solutions can also be
used as sustained-release oral formulations,[33,
mucoadhesive films.[38,

59, 60]

54-57]

biodegradable implants,[58] and

With the same formulation, the release rate of

chlorpheniramine maleate (CPM) is lower for HME samples as compared to powder
compressed samples (Figure 1.9).[61]
Although the extrusion technology has been realized by the pharmaceutical
industry since 1971 (Figure 1.10), broader applications of HME are often limited by two
common technical challenges. One is that the APIs may degrade at the elevated
processing temperatures during the extrusion process. To avoid this problem and yet
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obtain a well-mixed dispersion of API and polymer, the extrusion needs to be carried out
in an optimal processing window, where the temperature is kept safely below the API’s
degradation temperature and kept in the HME equipment for a short time. Another
challenge is the potential physical instablility of extrudate during its shelf life, which
involves the API’s recrystallization from the amorphous solid solution achieved at the
Tprocess through HME. The API’s solubility can decrease significantly once the
temperature is dropped from the HME processing temperature to the storage temperature,
e.g., ambient temperature. As a result, the API may phase separate from the polymeric
matrix and recrystallize.[47, 62] Different strategies can be applied to address this issue
depending on the specific application and the material system. One common way to
prevent recrystallization is to select a suitable polymer for a given API.[9, 63-65] However,
considerable development time is needed to identify the appropriate formulations
experimentally. Other methods such as utilizing polymer blends[66, 67] and additives[68]
might also help to inhibit API’s recrystallization.

Figure 1.9 Chlorpheniramine maleate (CPM) release profiles from directly compressed
(left) and HME (right) samples in 900 ml of 0.1N HCl (♦), pH 4.0 acetate buffer (◊), pH
4.0 citrate buffer (▲), pH 4.0 phosphate buffer (Δ), pH 6.8 phosphate buffer (■) and pH
7.4 phosphate buffer (□).[61]
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Figure 1.10 Historical perspective of pharmaceutical hot-melt extrusion.[69]

To address the aforementioned two challenges, it is critical to determine
experimentally the API’s solubility in a polymeric excipient at both processing and
storage temperatures. There are very few publications devoted to such solubility studies,
all of which utilized only amorphous polymers with high glass transition temperature (Tg)
such as PVP, PVP/VA, PVAc (polyvinyl acetate) and Eudragit® E.[70-74] API-polymer
powder mixtures were heated at very slow rates using a differential scanning calorimeter
(DSC) to determine the depressed melting points (Tmmix) of the APIs. Phase diagrams
were plotted between the Tg of the polymer and the melting point (Tm) of the pure API,
from which the API’s solubility at HME processing temperature could be read (Figure
1.11-1.13). The method requires an “appreciable” thermal effect associated with the API
dissolution process in order to determine Tmmix. None of the studies provide direct
experimental data regarding the solubility in highly viscous PVP and PVP/VA at room
temperature. The difficulty lies in the fact that the kinetics of reaching the drug-polymer
equilibrium are extremely slow.
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Figure 1.11 Melting point (Tend) and glass transition (Tg) of (a) indomethacin (IMC) and
(b) nifedipine (NIF) - polymer mixtures at various drug loading.[70]

Figure 1.12 DSC thermograms of physical mixtures of indomethacin with increasing
volume fraction of PVP K12 measured at a heating rate of 1 oC/minute. Onset of the
melting (□), offset of melting (◊) and predicted melting point depression for an athermal
mixture (enthalpy of mixing ∆H is zero, dashed line).[71]

Figure 1.13 DSC thermograms of physical mixtures of itraconazole with increasing
volume fraction of Eudragit® E measured at a heating rate of 1 oC/minute. Onset of the
melting (□), offset of melting (◊) and predicted melting point depression for an athermal
mixture (enthalpy of mixing ∆H is zero, dashed line).[71]
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A more fundamental understanding of the miscibility of API-polymer mixtures is
much needed for the pharmaceutical industry to embrace solid dispersion/solution
technologies such as HME. Theoretically, the miscibility of any two components is
governed by their Gibbs free energy of mixing (∆Gm).

∆Gm = ∆H − T∆S

(1.1)

The entropy of mixing (∆S) is usually larger than zero and favors the mixing.
Negative enthalpy of mixing ∆H is beneficial for miscibility and solid dispersion
stabilization.[65, 75-77] ∆S is represented by the molecule size difference between the API
and the polymer. The larger the difference is, the larger the ∆S. ∆H is represented by the
intermolecular interaction between API and the polymer. The stronger the interaction is,
the more negative the ∆H. The entropic and enthalpic effects on ∆Gm will be discussed in
greater detail in Chapter 4.3.3. Based on this simple understanding of the
thermodynamics, much effort has been devoted to understand the role of API-polymer
molecular interactions and how they affect the drug’s solubility in the polymer and its
stability. However, beyond the above basic understanding, very limited literature
references have discussed theoretical methods that can be applied to predict API’s
solubility in polymers and the stability of the solid dispersions/solutions. The studies that
determined the APIs’ phase diagram at high temperatures use the Flory-Huggins model to
calculate APIs’ activities or solubilities in polymers with the interaction parameter χ
estimated from the melting point depression.[70-74] Theoretical treatment of polymer
solutions was initiated independently by Flory[78] and Huggins[79] in 1942. The FloryHuggins theory is based on the lattice model shown in Figure 1.14. In the case of the low
molecular weight solvent (Figure 1.14a), it is assumed that the solute and solvent
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molecules have roughly the same volumes, each occupies one lattice site. With the
polymeric solvent, Figure 1.14b, a segment of the polymer molecule has the same volume
as a solute molecule and also occupies one lattice site.

(a)

(b)

Figure 1.14 Lattice model of solubility: (a) low molecular weight solvent; (b) polymeric
solvent. ○, Solute; ●, Solvent.
By statistically evaluating the number of arrangements possible on the lattice,
Flory and Huggins obtained an expression for the entropy of mixing in forming a solution
from N1 moles of solute and N2 moles of solvent:

∆S = − R( N1 ln φ1 + N 2 ln φ 2 )

(1.2)

where the φ1 and φ2 are volume fractions of solute and solvent, respectively.
An expression for the enthalpy of mixing was obtained by considering the change
in the adjacent-neighbor (molecules or segments) interactions on the lattice:
∆H = RTχN1φ2
where χ is the Flory-Huggins interaction parameter.

(1.3)
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The activity coefficient of a drug in a polymer a1 is expressed as

ln a1 = ln

φ1
x1

+ (1 −

1
)φ 2 + χφ 22
m

(1.4)

where φ1 is the volume fraction of the drug, φ2 is the volume fraction of the polymer, m
is the molar volume ratio of a polymer molecule to a drug molecule, and χ is the FloryHuggins interaction parameter. The theoretical background on how to calculate activity
and solubility can be found in Chapter 4.3.1.
It was found that the model fits reasonably well the activities of indomethacin and
nifedipine dissolved in PVP, PVP/VA and polyvinyl acetate (PVAc) (Figure 1.15), but
works poorly with D-mannitol in PVP.[70] Two studies conducted by the same group
show that often predicted drug solubility in PVP and its derivatives is lower than the
experimentally obtained values.[71, 73] To explain the discrepancy, the authors postulated
that the kinetic factor also contributes to the inhibition of drug recrystallization, which is
not included in the Flory-Huggins model.

Figure 1.15 Activity a1 of (a) indomethacin (IMC) and (b) nifedipine (NIF) versus
polymer weight fraction w2. The solid curves are Flory-Huggins predictions.[70]
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1.4 Semi-crystalline Polymers
All previous literature studies address only few selected amorphous polymers. Not only it
is necessary to test the melting point depression methodology on more polymers to
understand its applicability, it is also of considerable fundamental and practical interest to
find out whether this widely used model can be used to understand the drug’s solubility
in semi-crystalline polymers. This is a more complicated topic because true solutions are
formed between the API and the molten polymer (above Tmmix), and during cooling of the
extrudate the dissolved API may interfere with the polymer chain folding involved in the
crystallization process.
Semi-crystalline polymers such as poly(lactic acid) (PLA), poly(vinylidene
fluoride) (PVDF) and poly(ester amide) (PEA) are often used in medical devices and
biodegradable implants.[80-82] Poly(ethylene oxide)s (PEOs) with molecular weight (MW)
of 1,500-20,000 g/mol, often referred as polyethylene glycol (PEG), are widely used for
the preparation of oral solid dispersions for dissolution rate and bioavailability
improvement.[14, 83, 84] High MW (>100,000 g/mol) PEOs, on the other hand, are often
chosen for the HME process because of their broad processing window[13] and they have
been used in applications such as sustained-release matrix systems, transdermal drug
delivery systems, and mucosal bioadhesives.[33,

38, 59, 67]

In semi-crystalline polymers,

drug diffusion can be hindered due to the presence of crystallites.[85] The volume fraction
and the size of the crystallites may affect the diffusion coefficient, and the influence of
these parameters is expressed in terms of tortuosity factors.[86-88]
The semi-crystalline polymer excipient used in this thesis is a relatively high MW
PEO, exhibiting spherulitic morphology under normal quenching. The crystallization of
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PEO,[89-93] its blends with other polymers,[94-99] nanocomposites[100,

101]

and block

copolymers[102] has been extensively studied over the past decades. In the miscible blend
system of poly(acetoxystyrene)(PAS)/PEO, the presence of the amorphous PAS phase
reduced the spherulitic growth rate of PEO (Figure 1.16).[94] The crystallization ability of
PEO increased with increasing PAS content as indicated by the decreasing nucleation
constant kg and surface free energy of the chain folding of PEO σe. Details on how to
measure these kinetic parameters can be found in Chapter 4.5.1. In other miscible blend
systems, however, the crystallization rate of PEO was found to decrease more
significantly in the presence of strongly interacting polymers as compared to weakly
interacting polymers.[95,

99]

Figure 1.17 demonstrates that at the same crystallization

temperature, PEO blends with the strongly interacting random copolymers of ethylene
and methacrylic acid (EMAA, 55wt% acid units) and styrene and hydroxystyrene (SHS,
50wt% hydroxystyrene) crystallize much slower than PEO blends with weakly
interacting poly(methyl methacrylate) (PMMA).[95] The long period of PEO, which is the
sum of the thickness of the crystalline lamellae and amorphous layer, increased by 2-4
nm for the PMMA/PEO blends, an effect associated with interlamellar diluent placement.
In the immiscible poly(ε-caprolactone) (PCL)/PEO blends, where both polymers are
semicrystalline, the crystallization rate of PEO decreased with increasing amount of
PCL.[97] The authors considered the slow-down of the crystallization rate to be caused by
the physical restriction to the growth of crystalline PCL domains. In the silica-PEO
nanocomposite system, the distribution of particle spacings in the semicrystalline state is
always significantly broader than in the melt, even though the mean particle spacing is
unchanged.[100] At low silica loading (<20 wt%), the crystallization polymer chains
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“force” the nanoparticles “defects” out of their way to crystallize in a minimally
perturbed form (Figure 1.18). Reversible de-intercalation and intercalation processes
were detected in PEO-Cloisite 15A (material properties will be discussed in Chapter 2.3)
nanocomposites during secondary crystallization and subsequent melting of the
secondary crystals (Figure 1.19).[101]

Figure 1.16 Spherulite growth rate (G) as a function of crystallization temperature (Tc)
for PAS/PEO blends.[94]

Figure 1.17 Wide angle X-ray diffraction (WAXD) measured crystallinity as a function
of crystallization time for PEO and blends crystallized at 48 oC.[95]

23

Figure 1.18 Crystallization in the presence of brush-coated nanoparticles. In welldispersed nanocomposites, the growing lamellae can maneuver the nanoparticles, thereby
broadening interstitials to allow bulk-like lamellae to form.[100]

Figure 1.19 Schematic representation of the morphology in the PEO/Cloisite® 15A
nanocomposite after PEO primary crystallization.[101]

The drug-PEO system studied in this thesis is more complicated than the miscible
polymer blends, immiscible blends and nanocomposite systems. The drug’s physical
state, size, and miscibility with PEO, all play important roles in PEO’s crystalline
morphology, spherulite growth rate, and nucleation. One may be able to determine the
APIs’ solubility by observing the morphological change, spherulitic growth rate and
number of nuclei.

CHAPTER 2
MATERIALS

2.1 Acetaminophen
Acetaminophen (APAP), also called paracetamol, is the active ingredient in Tylenol®
(Figure 2.1). It is used to relieve mild to moderate pain from headaches, muscle aches,
menstrual periods, colds and sore throats, toothaches, backaches, and reactions to
vaccinations (shots), and to reduce fever. Acetaminophen may also be used to relieve the
pain of osteoarthritis (arthritis caused by the breakdown of the lining of the joints).
Acetaminophen is in a class of medications called analgesics (pain relievers) and
antipyretics (fever reducers). It works by changing the way the body senses pain and by
cooling the body.[103] When taken at recommended doses, APAP has an excellent safety
profile, notably lacking the gastrointestinal (GI) side effects of aspirin and ibuprofen.[104]
However, acute overdosaging with acetaminophen, whether accidental or deliberate, is
relatively common and can be very serious. Ingestion of 10-15 g of acetaminophen by
adults can cause severe hepatocellular necrosis and doses of 20-25 g are potentially
fatal.[74, 105]

Figure 2.1 Chemical structure of acetaminophen.
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Crystalline APAP has two common polymorphs, which are the monoclinic (form
I)[106] and the orthorhombic (form II).[107] Monoclinic APAP is thermodynamically more
stable at room temperature with respect to the orthorhombic modification.[108] The APAP
synthesized by the manufacturers is in form I. Form II was shown to be more soluble[109]
and directly compressible into tablets.[110] Despite considerable effort by researchers, its
production in pure form from solution has remained elusive.[111] Figure 2.2 shows
microscope pictures of monoclinic and orthorhombic APAP growing from different
polymer solutions.[112] Their X-ray diffraction (XRD) patterns also exhibit distinct
differences shown in Figure 2.3.[112] The melting point of the monoclinic form is 170 ºC
and of the orthorhombic form is 158 ºC based on the DSC results (Figure 2.4). The raw
crystalline and the recrystallized APAP in this thesis is in the monoclinic form and
therefore the polymorphism will not be further discussed.

Figure 2.2 Monoclinic APAP growing from beads of butyl methacrylate/isobutyl
methacrylate copolymer (left); and orthorhombic APAP growing from powdered
poly(tetrafluoroethylene) (right).[112]
Raw acetaminophen was purchased from Spectrum Chemicals (Gardena, CA) and
was used without further purification. It is a white powder and the crystals are of rod
shape, with the length of one particle about 100 µm (Figure 2.5a). Since the particles are
quite brittle, the powder also includes a significant amount of fine particles, ~5 µm in size
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(Figure 2.5b). The molecular weight of APAP is 151.19 g/mol and the density is 1.293
g/cm3. The glass transition temperature of amorphous acetaminophen is 24.5 ºC (Figure

Intensity (a.u.)

2.6).

Figure 2.3 Powder X-ray diffraction (XRD) patterns of APAP polymorphs grown from
aqueous solution.[112]

Figure 2.4 Melting peaks of monoclinic (top) and orthorhombic (bottom) acetaminophen
in DSC at a heating rate of 10 ºC/minute.
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Figure 2.5 APAP particles under (a) polarized microscope, and (b) scanning electron
microscope (SEM).

Figure 2.6 Glass transition of amorphous APAP determined from 2nd heating of
crystalline APAP in DSC.
APAP’s solubility in water is 14.9 mg/g at 25 ºC[113] and 23.7 mg/g at 37 ºC.[114]
According to the biopharmaceutical classification system (BCS),[115] acetaminophen is a
BCS class III drug,[116] which has high solubility in the aqueous medias over the pH range
of 1 to 7.5 but low intestinal permeability. Grattan et al. showed that the addition of
sodium bicarbonate to APAP formulation produced a faster and higher peak
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concentration in plasma even though the dissolution profiles were similar.[117] This
example shows that even though formulation change may seem completely innocuous, it
may very well alter the plasma profile if the new excipient alters GI physiology.
Thermogravimetric analysis (TGA) of APAP was performed in air and N2
environments (Figure 2.7). Degradation onsets of the two curves are very close, and
APAP is thermally stable until 177 oC (higher than its Tm of 170 oC) in N2 environment.
The hot-melt mixing temperature of 120 oC used in this thesis (Chapter 3.1) is well below
the 177 oC and, thus, safe for APAP processing.

Figure 2.7 Weight loss of APAP during TGA at 10 oC/minute heating rate in air (solid)
and N2 (dashed).

2.2 Poly(ethylene oxide)
Poly(ethylene oxide) (PEO) is a semi-crystalline polymer and is often chosen as the solid
dispersion excipient for HME because of its broad processing window.[13] Polyethylene
glycols (PEGs) with molecular weight of 1,500-20,000 g/mol, which are smaller
molecular weight analogues but have the same molecular structure as PEO (Figure 2.8),
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are often used for the preparation of oral solid dispersion for dissolution rate and
bioavailability improvement.[14, 83, 84] PEG 300 (MW of 280-320 g/mol) and PEG 400
(MW of 380-420 g/mol) are widely used in injectable formulations when pH adjustment
alone is insufficient in achieving the desired solution concentrations.[118] High MW PEO
has been used in applications such as sustained-release matrix systems, transdermal drug
delivery systems, and mucosal bioadhesives.[33, 38, 59, 67] The influence of PEO molecular
weight on the dissolution profiles are illustrated in Figure 2.9, showing that the drug
release rate is slower by using higher MW PEO.[56] The PEO used in this thesis is in
powder form and is kindly donated by the Dow Chemical Co. (Midland, MI). It is a
POLYOXTM Water-Soluble resin and is a nonionic polymer. The company markets
different PEO grades with molecular weights ranging from 100,000 to about 8,000,000
g/mol. WSR N10 is the one used in this thesis, whose weight average molecular weight
Mw is 100,000 g/mol and its density ρ is 1.13 g/cm3.

Figure 2.8 Chemical structure of PEO.

The melting and glass transition temperatures of PEO are 62.5 ºC (Figure 2.10)
and -56.6 oC (Figure 2.11), respectively. The degree of crystallinity is about 80%, based
on the heat of fusion of the “perfectly” 100% crystalline PEO being 203 J/g.[119] TGA of
PEO was performed in air and N2 environments (Figure 2.12). Unlike APAP, PEO is
susceptible to oxidation as well as thermal degradation and its weight loss in air is much
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more severe than that in N2. To prevent PEO from such degradation, N2 purge was used
during the hot-melt mixing in this work (Chapter 3.1).

Figure 2.9 Dissolution profiles of hot-melt extruded mini-matrices containing 30%
metroprolol tartrate (MPT) and 70% hydrophilic polymer: PEG 6000 (■), PEO 100,000
(▲), PEO 1,000,000 (●) and PEO 7,000,000 (□).[56]

Figure 2.10 Melting peak and heat of fusion of PEO N10 in DSC at heating rate of 10
ºC/minute.
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Figure 2.11 Glass transition of amorphous PEO N10 in DSC at a heating rate of 10
ºC/minute.

Figure 2.12 Weight loss of PEO during TGA at 10 oC/minute heating rate in air (solid)
and N2 (dashed).

The oxidative degradation of powdered PEO resin was studied by Scheirs et
al.[120] Powdered PEO readily oxidizes under mild ageing conditions (60°C) owing to its
large surface area, its weak crystalline lattice and the weak carbon-oxygen bonds in its
backbone. As a result, its physical properties deteriorate after an induction period of
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about 23 days and, in the extreme cases, the free-flowing powder is transformed into a
soft wax. With increasing oxidation, there is also a pronounced change in the morphology
of PEO from a spherulitic to an axialitic structure. This transition is due to oxidatively
induced changes in molecular weight and dispersity that affect the crystallization
conditions. The emergence of multiple DSC melting peaks after oxidation indicates that a
number of low-melting, low-molecular-weight fractions are formed as a result of chain
scission processes. Such degradation was not observed in the current study because all
powdered PEO was stored in a sealed container at room temperature, supported by the
evidence of a single DSC melting peak (Figure 2.10) and the fact that the powder
remained free-flowing. N2 purge was used during hot-melt mixing (HMM) to reduce the
chance of oxidation degradation. The morphology of quenched HMM-prepared PEO is
spherulitic with spherulite size, depending on crystallization temperature Tc, as large as
1mm, indicating a pure, not degraded sample (Figure 2.13). In practice, antioxidants such
as Vitamin E and its derivatives, Vitamin C (ascorbic acid) and butylated hydroxyanisole
(BHA) have been used in pharmaceutical preparations and these compounds have been
found to suppress free radical production in photoirradiated phenol-melamine.[121]

Figure 2.13 Typical polarized micrographs of PEO spherulites.
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2.3 Nanoclays
Two commercial nanoclays, Cloisite® 15A and 30B were received as samples from
Southern Clay Products (Gonzales, TX). Cloisite® 15A is a natural montmorillonite
(MMT) modified with dimethyl, dehydrogenated tallow and quaternary ammonium
cations, while Cloisite® 30B is a montmorillonite modified with bis-(2-hydroxyethyl)
methyl tallowalkyl ammonium cations (Figure 2.14). Cloisite® nanoclays are surface
treated to be compatible with a whole host of systems. Cloisite® 15A is the most
hydrophobic and Cloisite® 30B is the most hydrophilic member in the surface treated
Cloisite® family (Figure 2.15). A Cloisite® particle of 8 microns contains over 1,000,000
platelets stacked together. Extremely large interfacial area between the clay and the
polymer can be obtained if the platelets can be separated, that is exfoliated, from each
other after the clay is processed together with a polymer. Because of this unique property,
nanoclays have the potential of being used in the polymer industry to slow down the
diffusion of gaseous molecules through various polymers, creating “barrier” films or
enclosure structures.

HT: hydrogenated tallow (~65% C18; ~30% C16; ~5% C14)
T: tallow (~65% C18; ~30% C16; ~5% C14)
Figure 2.14 Chemical structures of Cloisite® 15A (left) and Cloisite 30B® (right).
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Figure 2.15 Cloisite® Selection Chart Based on Polymer/Monomer Chemistry.[122]

Three types of polymer layered silicate nanocomposites may be obtained while
nanoclays are incorporated into the polymer, as illustrated in Figure 2.16.[123] When the
polymer is unable to intercalate between the silicate sheets, a phase-separated composite
is obtained, whose properties stay in the same range as that of traditional
microcomposites. On the other hand, in intercalated nanocomposites, the insertion of a
polymer matrix into the layered silicate structure occurs in a crystallographically regular
fashion, regardless of the clay to polymer ratio.

In such structures, a well-ordered

multilayer morphology built up with alternating polymeric and inorganic layers is
generated. Normally, only a few molecular layers of polymer can be intercalated in these
materials.[124] Small angle X-ray scattering (SAXS) results show that at 2% Cloisite® 15A
loading, the silicate nanoparticles entered into the PEO lamellae, increased the lamellae
thickness while decreasing the distance between two lamellae (Figure 2.17).[125] At 4%
loading, however, nanoparticles gathered in the amorphous regions between lamellae,
possibly because the crystal lamellae cannot “include” so many particles, and increased
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the amorphous layer thickness. The crystallization rate of PEO was accelerated by the
addition of Cloisite® 15A.

Figure 2.16 Different types of composites from the interaction of layered silicates and
polymers: (a) phase-separated microcomposite; (b) intercalated nanocomposite and (c)
exfoliated nanocomposite.[123]
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Figure 2.17 Small angle X-ray
scattering (SAXS) measured (a) The
long period, (b) lamellae layer
thickness, (c) amorphous layer
thickness and (d) the volume fraction
of semi-crystalline material of pure
PEO and the PEO/montmorillonite
(MMT) nanocomposites with 2 and
4%MMT during isothermal
crystallization of 48 oC.[125]
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Homminga

et

al.

found

some

very

interesting

results

on

poly(ε-

caprolactone)(PCL)/Cloisite® 15A nanocomposites.[126] First of all, there is significant
morphological difference between PCL/Cloisite® 15A samples (Figure 2.18) and
PCL/Cloisite® Na+ unmodified sample (Figure 2.19). The observed black lines in Figure
2.18 cannot be interpreted as individual silicate layers as they are too large and thick. The
size and shape of the lines in the TEMs supports the view of intercalated stacks. In
contrast, Cloisite® type MMT without surfactants cannot be intercalated and the original
MMT stack is fully preserved even after mixing with PCL. These clay aggregates are
larger, less diffuse and darker as compared to the intercalated, and most likely partially
broken-up stacks seen in Figure 2.19. The second finding is that all nanocomposites
display a pronounced decrease in amorphous layer thickness as shown in Figure 2.20,
which is a signature of secondary crystallization via the insertion of new crystals in
between already existing ones. Primary crystallization is defined as the growth of
spherulites, involving primary crystals in rather open “primary stacks”. Behind the
spherulitic growth front another one follows much slower, involving further and delayed
conversion of amorphous material that was left amorphous in the primary stacks by the
insertion of new crystals. The overall crystallinity is significantly improved in the
presence of MMT as well.
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Figure 2.18 Transmission electron micrographs (TEMs) of poly(ε-caprolactone) and its
Cloisite® 15A composites.[126]

Figure 2.19 TEM of poly(ε-caprolactone) +8% Cloisite® type MMT without surface
modification.[126]
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Figure 2.20 Small angle X-ray
scattering (SAXS) measured (a) The long
period, (b) lamellae layer thickness, (c)
amorphous layer thickness and (d) the
volume fraction of semi-crystalline
material of pure PCL and the PCL/MMT
nanocomposites during isothermal
crystallization of 47 oC.[126]

40
Melt-mixed PEO/Cloisite® 30B, on the other hand, formed exfoliated
nanocomposites with no clear SAXS peaks of PEO (MW 100,000) (Figure 2.21) and
lower PEO crystallinity.[127] Park et al. have developed a method of inserting and
stabilizing donepezil molecules in the interlayer space of clay via mono or double layer
stacking (Figure 2.22).[128] The nanoclays they used were Na+-MMT, Na+-saponite (SA)
and Na+-laponite (LA), whose chemical formulae can be found in their paper.[128] By
making hybrids where donepezil molecules intercalated into the smectite clays,
controlled release drug delivery systems were achieved (Figure 2.23).

Figure 2.21 SAXS spectra of PEO/Cloisite® 30B nanocomposites.[127]
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Figure 2.22 Schematic diagrams of the arrangement of the intercalated donepezil in
nanoclay materials: (a) double layer arrangement in donepezile-MMT and (b) monolayer
arrangement in donepezile-LA.[128]

Figure 2.23 Release profiles of donepezil in pH 1.2 HCl from the Eudragit® E coated
hybrids. The hybrids are (a) donepezil-MMT, (b) donepezil-SA and (c) donepezil-LA.[128]

CHAPTER 3
EXPERIMENTAL

3.1 High Temperature Solubility Measurement
3.1.1 Sample Preparation – Hot-melt Mixing (HMM)
The APAP-PEO mixture samples with twelve APAP weight percentages of 0, 1, 2, 3, 4,
5, 10, 20, 25, 30, 40, 50 and 60% were prepared by hot-melt mixing under a N2 purge
blanket using a Brabender FE-2000 batch intensive mixer with two counter rotating
screw melting/mixing elements (Figure 3.1). 50 g of pre-mixed powders was processed
for each batch at a mixer temperature of 120 ºC and rotor speed of 50 rpm. After 10
minutes of mixing, the melt was removed from the mixer and compression molded at 120
ºC into 25 mm diameter × 1 mm thickness discs as well as 14 × 10 × 2.7 mm bars
separately. The evolution of the torque during mixing of 30%APAP-PEO is given as an
example in Figure 3.2. The increase of the torque value at the beginning represents the
feeding surge. After that, the torque value decreases until it reaches a plateau. It takes
about 5 minutes for the torque to reach a constant value. The drop of the torque is due to
the viscosity decrease of the mixture, which is caused not only by the melting of PEO,
but also by the dissolution of the APAP molecules into the highly viscous polymer melt.
Detailed rheological results are presented in Chapter 4.1.1. Simply put, the dissolved
APAP acts as a plasticizer and lowers the viscosity of the mixture. A constant torque
value indicates that 10 minutes is sufficient time for complete mixing. All samples were
cooled down to 25 ºC with cooling water circulated in the compression mold. They were
stored at room temperature in a vacuum desiccator with silica gel before further testing.
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Figure 3.1 Brabender FE-2000 batch mixer with two counter rotating screws.

Figure 3.2 The evolution of torque during melt mixing for 30%APAP-PEO.

As mentioned in Chapter 1, the rotation speed and the residence time have been
optimized to achieve a well-mixed and homogeneous mixture. 120 oC is a safe
temperature for both APAP and PEO (Figures 2.7 and 2.12). For drug loadings ≤ 30%,
APAP could completely dissolve in PEO at 120 oC (results in Chapter 4.1). For higher
drug loading samples (APAP ≥ 40%), the purpose of the batch mixing is to prepare well-
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distributed mixtures and suspensions for the solubility studies. As mentioned earlier, N2
purge was used to prevent PEO from oxidative degradation (Chapters 1 and 2). All
processing conditions are fixed as the focus of this thesis is the experimental and
thermodynamic study of drug-polymer miscibility in HMM-prepared APAP-PEO
systems of a wide range of APAP concentrations, determined over a wide range of
temperatures from ambient to processing.

3.1.2 Rheological Experiments
The Rheometrics Mechanical Spectrometer RMS-800 from Rheometrics Scientific (now
TA Instruments, New Castle, DE) was used to determine the steady viscosity of PEO and
its mixtures with APAP. A step rate rotational flow test was conducted at a constant shear
•

rate ( γ ) of 0.5/s using 25 mm parallel plates. The PEO and APAP-PEO could achieve a
steady-state stress and thus, viscosity, at this shear rate. A sample disc (25 mm diameter ×
1 mm thickness) was loaded between the plates at 140 °C but was quenched to the testing
temperatures (Tf) in less than 2 minutes. It was held isothermally at Tf for 15 minutes to
reach equilibrium before testing. Each sample was tested individually at Tf values of 80,
100, 120 and 140 °C for 10 minutes.
A schematic drawing of a parallel plate set-up is presented in Figure 3.3.[129] The
viscosity η is calculated by measuring experimentally the shear stress τ at a constant
•

longitudinal shear rate γ .
•

η =τ /γ

(3.1)
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Torque Γ

× angular velocity

Γ

Figure 3.3 A schematic drawing of a parallel plate set-up.[129]

3.1.3 Hot-stage Microscopy (HSM)
Mixtures of 10, 20, 30, 40 and 50 wt% of APAP in PEO were examined by hot-stage
microscopy using an optical microscope (Carl Zeiss Universal Research Microscope)
equipped with a Zeiss AxioCam MRc5 (5MB-pixel resolution) digital camera and
coupled with a Mettler FP82HT hot stage and Mettler FP90 temperature controller
(Mettler-Toledo Inc., Columbus, OH, USA). Samples were heated between two glass
slides from room temperature to a final temperature (Tf) of 80, 100, 120, and 140 ºC at a
heating rate of 10 ºC/minute and kept isothermally at Tf for 15 minutes. Images were
taken during and at the end of the experiment.
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3.1.4 Differential Scanning Calorimetry (DSC)
DSC measurements were carried out using a TA Instruments Q100 (New Castle, DE)
equipped with a refrigerated cooling system. The chamber was flushed with N2 at a flow
rate of 40 ml/minute during testing. A sample of about 4 mg was weighed and placed in
an aluminum pan with lid and crimp sealed. The glass transition temperatures (Tgs) of
PEO and APAP were measured in the 2nd heating cycle of a heat-cool-heat loop. Pure
PEO was heated from 30 ºC to 80 ºC at 10 ºC/minute, quenched to -80 ºC and reheated to
80 ºC at 10 ºC/minute. Pure APAP powder was heated from 30 ºC to 180 ºC at 10
ºC/minute, quenched to -25 ºC and reheated to 180 ºC at 10 ºC/minute.
Binary mixture samples, with 10, 20, 25, 30, 40, 50 and 60 wt% of APAP, were
examined using the following heat-cool-heat cycle for determination of the glass
transition temperature Tg of the mixture, which were further utilized to estimate APAP’s
solubility at high temperatures, i.e., above the PEO’s melting point, and the melting
temperature Tm of the mixture.
1: A sample was heated from 30 ºC at 10 ºC/minute to a final temperature (Tf) of 80, 100,
120 or 140 ºC, at which temperature it was held isothermally for 15 minutes.
2: The sample was quenched from Tf to -80 ºC at 20 ºC/minute.
3: The sample was reheated from -80 ºC to 80 ºC at 10 ºC/minute to measure Tg and Tm.
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3.2 Apparent Room Temperature Solubility Measurement
3.2.1 Sample Preparation - HMM
The same APAP-PEO mixture samples as in Chapter 3.1.1 were used for the
determination of the apparent room temperature solubility. APAP-nanoclay-PEO
mixtures, with APAP concentrations ranging from 10, 20 and 30wt%, and nanoclay
Cloisite® 15A and 30B concentration kept constant at 10wt%, were prepared by using
the same hot-melt mixing procedure.

3.2.2 DSC
APAP’s apparent solubility in PEO at room temperature was estimated by Tg
measurement in a single heating ramp. Samples were stored at room temperature for four
weeks. APAP-PEO mixtures with APAP concentration varying from 1 to 50% were
quenched to -80 ºC and then heated to 80 ºC at 10 ºC/minute. The melting temperature
onset Tm was also recorded in the same cycle.

3.2.3 Dynamic Mechanical Thermal Analysis (DMTA)
Dynamic Mechanical Thermal Analyzer DMTA-IV from Rheometrics Scientific (now
TA Instruments, New Castle, DE) was used to determine the Tgs of pure PEO and its
mixtures with APAP that were stored at room temperature for four weeks after hot-melt
mixing. The experiment was conducted using a dual cantilever with a small frame. A
sample bar (14 × 10 × 2.7 mm) was first quenched to -70 °C and then ramped to 30 °C at
a heating rate of 2 °C/min using liquid nitrogen as a cooling medium and 5 ml/minute N2
gas to prevent the build-up of moisture during the experiment. A strain of 0.02%, within
the linear viscoelastic region of the material (that is below the strain limit of linear
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viscoelastic response), and a frequency of 1 Hz were applied for each sample. The elastic
(in-phase) modulus (E’), viscous (out-of-phase) modulus (E”) and tan δ (E”/E’) were
recorded during the experiment. Tg was determined from the peak of the tan δ curve in
the glass transition region.
The modulus of a material E is defined as:

E=

τ
γ

(3.2)

where τ is the stress and γ is the strain. The viscoelastic properties of the APAP-PEO
systems were studied by dynamic mechanical analysis where a sinusoidal strain was
applied and the resulting stress was measured. For an ideally elastic solid, the resulting
stress and the strain will be perfectly in phase. For a purely viscous fluid, there will be a
90o phase lag of stress with respect to strain.[130] In the dynamic mechanical test, stress
and strain are expressed as:

τ = τ 0 sin(tω + δ )

(3.3)

γ = γ 0 cos(tω)

(3.4)

where ω is the frequency of strain oscillation, t is the time and δ is the phase lag between
stress and strain. By definition, the elastic (in-phase) modulus E’, viscous (out-of-phase)
modulus E” and phase angle δ are described as:

E' =

τ0
cos δ
γ0

(3.5)

E" =

τ0
sin δ
γ0

(3.6)

tan δ =

E"
E'

(3.7)
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3.2.4 Scanning Electron Microscopy (SEM)
Morphologies of binary and ternary mixture samples were examined using a LEO 1530
Field Emission Scanning Electron Microscope (Carl Zeiss SMT Inc., Peabody, MA) at 2
keV. Both the surfaces and cryo-fractured surfaces of the samples were characterized.
The cryo-fractures were prepared by snapping a sample disc that had been soaked in
liquid nitrogen for 5 minutes. All samples were sputtered with a thin layer of carbon to
improve the electrical conductivity prior to imaging.

3.2.5 X-ray Diffraction (XRD)
A Philips PW3040 X-ray diffractometer (PANalytical Inc., Westborough, MA) was
controlled by X’Pert software with Cu Kα radiation (λ = 1.54 Å) generated from a copper
source operating at a power level of 40 KV and 40 mA. The sample discs were held
directly for XRD analysis and scanned over the 2θ range of 5–30º at the step size of
0.03º/step and the scan rate of 1 second/step. The slit configuration was 1.0º, 1.0º and
0.1mm for divergence, anti-scatter and receiving slit, respectively.

3.3 Determination of Flory-Huggins χ Parameter from Melting Point Depression
3.3.1 Melting Point Determination
The melting point Tm and heat of fusion ∆fusH of crystalline APAP were measured by
heating APAP from 298.15 K to 473.15 K at a heating rate of 10 K/minute in DSC. The
polymer-depressed drug’s melting points at different PEO weight percentage, namely
100, 90, 80, 75, 70, 60, 50 and 40%, were determined from high temperature solubility in
Chapter 3.1.
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3.3.2 Determination of Acetaminophen’s Solubility in PEG 400
APAP’s solubility in PEG 400, a small molecular weight analogue of PEO N10, was
measured using an Agilent 8453 UV Spectrophotomer (Foster City, CA) at wavelength of
243 nm. An excess amount of APAP was added to a capped glass bottle containing PEG
400 maintained at 300 K and was stirred vigorously for 48 hours. The resulting
suspension was filtered using a Millipore 0.2 µm PVDF syringe filter (Millipore Corp.,
Billerica, MA). Samples were diluted with DI water and the UV readings were compared
to a calibration curve.

3.4 Dissolution Testing
Dissolution tests on binary and ternary mixture samples were performed under the sink
condition using a Distek 2100A USP standard dissolution apparatus with a basket stirrer.
The dissolution medium (900ml of aqueous buffer solution with pH=7) was maintained
at 37±0.5ºC and stirred at 50 rpm. At predetermined intervals, 5 ml of solution was
withdrawn and the volume change was corrected in the calculation. The liquid was
filtered with a Millipore 0.45µm PVDF filter and analyzed using 10mm quartz cells and
an Agilent 8453 UV Spectrophotometer (Foster City, CA) at 243nm. Each of the tests
were performed three times to check repeatability.
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3.5 Crystallization of PEO and APAP-PEO
3.5.1 Sample Preparation – Solvent Evaporation
The APAP-PEO mixtures containing 0, 0.1, 1, 2, 10 and 20% by wt. APAP were
prepared by dissolving both materials in acetone/water and drying the solution in a
vacuum oven at room temperature for 24 hours. The dry films were about 140 µm thick
and were stored in a vacuum desiccator with silica gel before further testing.

3.5.2 Polarized Optical Microscopy (POM)
Pure PEO or APAP-PEO mixtures were placed on a glass slide and left on a hot plate at
130 ºC, when both PEO and APAP were fully melted based on results of the solubility
study at that temperature (Figure 4.8). Since the films were very thin (140 µm), it took
less than 30 seconds for complete melting (confirmed under polarized light) and ready for
optical microscope observation. After 30 seconds of heating, the sample was quickly
transferred to a Mettler FP82HT hot stage (Mettler-Toledo Inc., Columbus, OH, USA)
that was equilibrated at different crystallization temperature (Tx) (Table 3.1). The
morphology, number and size of the spherulites were monitored under a polarized optical
microscope (Carl Zeiss MicroImaging, LLC, Thornwood, NY, USA). The growth of the
spherulites as a function of time was recorded until spherulite impingement and the
diameter of the spherulites was measured directly from the monitor screen using the
length measurement function in AxioVision software. Reported spherulitic growth rates
(G) were determined as the average rates from 6-12 spherulites of three to six samples.
The standard deviation on the average growth rates was less than 5% of the magnitude of
G.
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Table 3.1 Crystallization Temperatures Tx Used in POM and Tc Used in DSC
PEO
Tx

51

50

49

48

47

46

Tc

50

48

46

44

42

40

Tx

50

40

30

Tc

52

50

48

46

44

42

Tx

50

40

30

Tc

52

50

48

46

44

42

Tx

50

49

48

47

46

45

Tc

52

50

48

46

44

42

Tx

50

49

48

47

46

45

Tc

52

50

48

46

44

42

Tx

46

45

44

43

42

41

Tc

46

44

42

40

38

36

45

40

30

40

30

0.1%APAP-PEO

1%APAP-PEO

2%APAP-PEO
44

10%APAP-PEO
44

20%APAP-PEO
40

All values in ºC

3.5.3 DSC
DSC measurements were carried out using a TA Instruments Q100 (New Castle, DE)
equipped with a refrigerated cooling system. The chamber was flushed with N2 at a flow
rate of 40 ml/minute during testing. Samples were cut to nearly identical shape, and the
sample weight was kept low (1.000 ± 0.050 mg) to minimize thermal lag during heating.
During the isothermal crystallization experiment, a sample was first heated to 130 ºC and
kept isothermally for 1 minute. It was then quenched to a specific crystallization
temperature Tc (Table 3.1) and was kept isothermally for a sufficient period to allow
complete crystallization. The sample was then heated to 90 ºC at 10 ºC/minute to
determine the melting temperature Tm (offset).
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Non-isothermal crystallization was carried out by using DSC to determine the
crystallization temperature (Tcp) and enthalpy (ΔHc). A sample was heated from 25 ºC to
130 ºC at 10 ºC/minute and kept isothermally for 1 minute to remove the thermal history.
It was then cooled to 25 oC at the rate of 10 ºC/minute and the Tcp was taken as the
maximum point of the exothermic peak.

CHAPTER 4
RESULTS AND DISCUSSION

4.1 High Temperature Solubility Measurements
4.1.1 Determination of Drug Solubility at Elevated Temperatures by Rheological
Analysis
The objective of the rheological study is to find drug’s solubility at different temperatures
within the extrusion processing window by tracking the viscosity change of the binary
mixtures with different drug loadings. The selected testing temperatures are above the
melting temperature of PEO (~62 ºC) and below the melting point of APAP (~170 ºC). In
this temperature range, if the APAP is not dissolved in the PEO, it will form a
suspension.
In general, steady viscosity (η) of PEO and APAP-PEO mixtures decrease with
increase in temperature due to increase of polymer chain mobility and reduction of
intermolecular forces. The viscosity results are plotted against APAP concentration in
Figure 4.1. The four viscosity curves at different Tf exhibit a similar trend, namely the
viscosity value drops first with increasing drug loading, and then increases after reaching
a certain concentration. The viscosity curve at Tf = 140 ºC, as an example, decreases from
6110 Pa·s for pure PEO to 430 Pa·s for 40 wt% of APAP, after which it climbs up to 691
Pa·s for 60 wt% of APAP. The initial decrease of viscosity indicates intermolecular force
weakening due to the drug dissolution.[131-133] That is, the dissolved APAP acts as a
plasticizer in this case, which leads to decrease of the viscosity with the increase of drug
concentration. On the other hand, the rise of the viscosity at higher drug concentrations
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occurs when the drug solubility limit is exceeded and the undissolved solid drug particles
act as suspended fillers. Extensive previous studies, starting with Einstein,[134] have
shown that the viscosity of a filler-polymer melt suspension system depends on the
interfacial energy as well as the filler’s concentration and shape.[135-138] Generally
speaking, the viscosity increases with the filler’s concentration,[139-141] which can be
explained by the increased viscous “drag” and dissipation due to the suspension and
particle/particle interactions at high concentrations. An example of the solid filler effect
is presented in Figure 4.2, where the zero-shear viscosity of PP(polypropylene) increases
appreciably with CaCO3 concentration.[141]

80oC

3x104

Viscosity η (Pa∙s)

100oC
120oC
3x103
140o
C
3x102
0

10

20
30
40
50
APAP Concentration (%)

60

70

Figure 4.1 Viscosity η curves of 0, 10, 20, 25, 30, 40, 50 and 60% APAP in PEO at
temperatures (Tf) of 80 ºC (Δ), 100 ºC (□), 120 ºC (◊) and 140 ºC (○).
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The viscosity data are further fitted with fifth-degree polynomial only to
determine the minimum value. Theoretically, the drug concentration with the lowest η is
the drug solubility at the specific temperature Tf. Dotted curves in Figure 4.1 were
obtained from polynomial fitting with R2>0.99 and the drug solubility values determined
from the fitting curves are listed in Table 4.1. The result shows that the drug solubility
increases steadily with temperature. It should be mentioned that the predicted solubility at
80 ºC (22%) may be slightly higher than the real value because the viscosity values of 20,
25 and 30 wt% of APAP are very close to each other, which makes it more difficult to
identify the critical point. These solubility data obtained by such a simple rheological
experiment is an original contribution of this thesis work and is of great value for
determining the processing window of HME. For example, to prepare a fully miscible
APAP-PEO system with drug loading of 20%, the lowest processing temperature is 100
ºC. Otherwise, the drug crystals will not fully dissolve into the polymer melt no matter
how intensive or how long the mixing is.

Figure 4.2 Zero-shear viscosity η0/ηp vs. filler volume fraction φ1. The solid data points
represent the simulation results based on Einstein’s theory. The open triangles represent
the experimental results using PP (polypropylene) and CaCO3 treated with stearic acid.
The horizontal line indicates mixture viscosity η0= pure polymer viscosity ηp.[141]
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Table 4.1 Summary of APAP Solubility in PEO at Elevated Temperatures Measured
with The Rheometrics Mechanical Spectrometer, Hot-Stage Microscope and DSC
Solubility by rheological

Solubility by hot-stage

Solubility by DSC

evaluation (%)

microscopy (%)

(%)

80 ºC

22

10 - 20

14

100 ºC

24

20 - 30

20

120 ºC

31

30 - 40

30

140 ºC

41

40 - 50

n.a.

Temperature

A low shear rate (0.5 s-1) was used in the rheological study so that the materials
remained as Newtonian flows under the testing conditions. If a high shear rate was used,
the materials would exhibit non-Newtonian behavior such as shear thinning, where the
viscosity would decrease with increasing shear rate. Shear thinning would diminish the
viscosity difference between samples with different APAP concentrations, which would
make it difficult to determine the minim on the viscosity curves in Figure 4.1.

4.1.2 Optical Determination of Drug Solubility at Elevated Temperatures
To check the solubility data obtained from the rheological test, a hot-stage microscope
(HSM) was used to directly observe the physical state of the drug particles in the molten
polymer mixtures. The same temperatures (Tf) as those in rheological experiments were
used. To facilitate observation and assure intimate contact between two materials, PEO
and APAP were first hot-melt mixed. The sample was placed on a glass slide, slightly
heated on the hot stage, and pressed carefully with a cover glass. The mixture was further
equilibrated at the temperature of interest. At Tf of 80 ºC and APAP loading of 10%
(Figure 4.3a), crystalline APAP fully dissolves in the molten PEO with no visible
particles observed. In contrast, at a drug loading of 20%, APAP crystals can be found
even after 15 minutes of heating at 80 ºC (Figure 4.3b). Therefore, APAP solubility at
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Figure 4.3 Hot-stage microscopic images of samples after being kept isothermally at
different temperatures for 15 minutes. a) 10% APAP-PEO at 80 ºC; b) 20% APAP-PEO
at 80 ºC; c) 20% APAP-PEO at 100 ºC; d) 30% APAP-PEO at 100 ºC; e) 30% APAPPEO at 120 ºC; f) 40% APAP-PEO at 120 ºC; g) 40% APAP-PEO at 140 ºC; h) 50%
APAP-PEO at 140 ºC.
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80ºC should fall between 10 and 20%. Experiments were also conducted at 100, 120 and
140 ºC (Figure 4.3c-h) and the results are summarized in Table 4.1. Clearly, most
solubility data obtained from rheological tests fall into the range determined by HSM.
The only slight mismatch was found at 80 ºC. As discussed in the previous section, the
critical point on the curve of viscosity versus drug loading cannot be accurately
determined at 80 ºC because the transition is not sharp enough. It should be mentioned
that the optical microscopy method is an approximate method and cannot be applied to
accurately identify the solubility value. Nevertheless it is quite straightforward, readily
accessible, and can be applied to obtain an “engineering” estimate of the solubility.
Another advantage is that the microscopy method, being straightforward, can be applied
to a wide range of drug-polymer systems compared to other analytical methods.

4.1.3 Determination of Drug Solubility at Elevated Temperatures Using DSC
A third approach using DSC was explored to determine the drug solubility at high
temperatures. The method is based on the assumption that the glass transition temperature
should vary with APAP’s concentration in the APAP-PEO solution. Similarly to the
rheological and microscopic analyses, temperatures within the HME processing window
were selected, namely 80, 100, 120 and 140 ºC. In the 1st heating cycle, the sample was
heated to a final temperature Tf and then held at the temperature for 15 minutes.
Depending on the drug loading and the temperature, the crystalline drug may be partially
or fully dissolved in the molten polymer at Tf. The sample was then quenched to -80ºC, a
temperature below the glass transition temperatures of both PEO and APAP. In the 2nd
heating scan, Tg of the APAP-PEO mixture was determined.
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Tg of PEO and APAP are -56.6 ºC and 24.5 ºC, respectively. Glass transition
temperatures of amorphous APAP-PEO from the 2nd heating cycle are plotted in Figure
4.4. One interesting finding is that the Tg behavior for Tf = 80, 100 and 120 ºC shows
quite a similar trend. Tg increases with APAP concentration but the glass transition
temperature stops rising after a certain drug loading. When the APAP concentration is
less than the critical value, APAP particles fully dissolve in the molten polymer at Tf
during the first heating scan. Beyond that limit, no more crystalline APAP can dissolve in
PEO and, thus, the curve reaches a plateau (in the case of 140 ºC, Tg dips at the region of
high drug loading, which will be discussed later). Hence, the critical concentration is
taken to be the drug’s solubility at Tf. The solubility data were summarized in Table 4.1.
It should be mentioned in this juncture that one assumption for the DSC method is that
the drug does not recrystallize during the quench and the second heating scan. The fact
that the solubility values predicted by all three methods are very close to each other in
this temperature range seems to support this assumption. Overall, the data show that the
solubility increases from 14% at 80 ºC to 41% at 140 ºC.
-10
-20

T g (oC)

-30
-40

80 oC
80oC
100 oC
100oC

-50

120 oC
120oC
140 oC
140oC

-60
0

10

20 30 40 50 60
APAP concentration (%)

70

Figure 4.4 Glass transition temperatures of mixtures at different drug loading
determined from the 2nd heating cycle in DSC with the ending temperatures (Tf) in the 1st
heating cycle of 80 ºC (Δ), 100 ºC (□), 120 ºC (◊) and 140 ºC (○), respectively.
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The following peculiar phenomenon is found on the curve corresponding to Tf of
140 ºC: the Tg drops as much as 17 ºC when the drug loading increases from 30% to 40%.
It is known from the rheological and microscopic analysis that drug solubility is around
41% at 140 ºC. Thus, the sharp Tg decrease is not caused by drug recrystallization or
phase separation. To further investigate this issue, the Fox equation[142] was used to
calculate the theoretical glass transition temperatures for APAP-PEO with different drug
concentrations and is expressed as:
w
w
1
= 1 + 2
T g Tg 1 T g 2

(4.1)

where w1 and w2 refer to the weight fraction and Tg1 and Tg2 refer to the glass transition
temperatures of the drug and polymer, respectively.
The Fox equation, as well as the Gordon Taylor (GT) equation expressed as
Equation (4.2),[143] are often applied to predict the glass transition temperature of random
copolymers[144-146] and plasticized polymers[147-149] based on compositions of two
components.
Tg =

w1Tg1 + Kw2Tg 2
w1 + Kw2

(4.2)

where wi is the weight fraction and Tgi the glass transition temperature of the blend
component i and K is an arbitrary fitted parameter. Ideal volume additivity was assumed
for the repeat units in the copolymer and the plasticizer-polymer blend for both of the two
original equations. Under that assumption, K is defined as the ratio of the differences of
the coefficients of expansion at Tg of the glassy state and rubbery state. Unlike the FloryHuggins theory as discussed in Chapter 1, neither the Fox nor the GT equation takes
intermolecular interactions into consideration.
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These two semi-empirical equations have been applied to drug-polymer and drugsalt systems to study the miscibility of the binary components.[76, 150-153] The Tg values of
these systems often do not agree with the GT predictions made on the assumption of ideal
mixing. A positive deviation was observed in the sodium indomethacin (NaIMC) and
indomethacin (IMC) system as shown in Figure 4.5.[152] The influence of molecular
interactions on the Tg of nonideal binary polymer blends has been explained in terms of
the relative magnitude of two different interaction energies: the interactions between like
molecules, or homo-contacts, and those between unlike molecules, or hetero-contacts.[154]
When the interaction between the hetero-contacts dominates the overall energies of the
system, the nonideally mixed system will have a Tg that is greater than that which would
be expected from the GT prediction. This appears to be the case for the NaIMC and IMC
solid solution. Because the GT prediction for an ideally mixed system is based on the
assumption that the free volume of the individual components is additive, a nonideal
system with a Tg value greater than that predicted from the ideal system would be
expected to have a free volume that is smaller than that of the ideal system. This is

Tg (oC)

supported by the increased true density values in the NaIMC and IMC solid solution.[152]

NaIMC Weight Fraction

Figure 4.5 Tg of coprecipitated sodium indomethacin (NaIMC) and indomethacin (IMC)
measured by DSC (♦) and predicted by the GT equation (solid line).[152]
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Similar positive Tg deviation was observed in the indomethacin-Eudragit® E
system (Figure 4.6),[153] which was most likely to be caused by the strong intermolecular
interactions between the indomethacin and Eudragit® E molecules.[19]

Figure 4.6 Tg of HME-prepared indomethacin and Eudragit® E measured by DSC (●)
and predicted by the GT equation (■).[153]

Since the APAP solubility is about 41% at 140 ºC, Tg is only calculated for
samples having less than 40% APAP loading. As shown in Figure 4.7, most experimental
Tg values are significantly higher than the theoretical values, suggesting possible specific
physical interactions between APAP and PEO. When APAP concentration is 40%,
however, the theoretical Tg is able to match the experimental value. The hydroxyl group
of acetaminophen is a good proton donor and can form strong hydrogen bonds with the
oxygen acceptor on the PEO chain,[155, 156] which is capable of leading to a nonlinear
relationship between Tg and the composition. Strong intermolecular interaction is usually
beneficial for miscibility and solid solution stabilization,[65, 75, 77] but the H-bonding in the
current case does not seem to prevent APAP from recrystallizing at room temperature.
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According to Wen et al., the high flexibility of PEG and the high mobility of the
functional groups involved in the H-bonds is the reason why the crystallization of APAP
cannot be inhibited.[157, 158] The unusual drop of Tg at drug concentration between 30 and
40% may be due to the saturation of hydrogen bond at high drug concentration.
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Figure 4.7 Calculated (◊) and DSC determined (Δ) glass transition temperatures of
APAP-PEO. Experimental data were obtained from the 2nd heating cycle in DSC with the
final temperature (Tf) in the 1st heating cycle of 140 ºC.

4.1.4 Phase Diagram of the APAP-PEO System
Figure 4.8 shows the relationships of polymer-depressed melting point of APAP Tmmix
and melting point of PEO Tm(PEO) with different APAP concentrations. APAP’s
solubility in the range of 80 to 120 ºC was determined by DSC analysis, while the
solubility at 140 ºC was estimated to be 41% based on the rheological evaluation method.
Tm(PEO) values were acquired from the 2nd DSC heating.
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Figure 4.8 Dissolution temperature Tmmix (□) and PEO melting point Tm (◊) of APAPPEO with different percentage of APAP dissolved.
The composite figure of Tmmix/Tm(PEO) vs. drug loading (Figure 4.8) is, in
essence, a “phase diagram”. Such “phase diagram” may provide valuable information for
API-excipient formulation and HME process development. HME is often processed at
temperatures above the Tm(PEO) curve where PEO is in the molten state. APAP and PEO
are fully miscible and form a liquid solution in region A. In region B, however, APAP
does not totally dissolve in PEO, and thus the system contains solid suspended drug
particles. In order to obtain a true solution, it is more favorable to process the mixture in
region A as compared to region B. Of course, other factors such as the potential of
thermal degradation need to be taken into consideration.
Insightful information regarding the mixture’s physical state can be obtained by
using the above three methods, i.e., rheological, microscopic and thermal analysis.
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Understandably, each method has its own limitations. The rheological method can only
be applied to study the upper range of the processing temperature due to the instrument’s
toque limitations. More specifically, rheometers generally can only be applied to study
the system at a temperature higher or significantly higher than the melting temperature of
the polymer excipient. For solubility determination, the temperature also needs to be
lower than the melting point of the pure drug. Otherwise, the drug will exist as a liquid
and increase of drug loading will lead to decrease of the viscosity of the mixture even if
the drug liquid is not fully miscible with the molten polymer. On the other hand, the
advantage of the rheological method lies in the relative simple relationship between the
viscosity and the mixture composition, which makes easy to identify the critical point in
the viscosity vs. composition curve, i.e., the solubility point range, compared to the DSC
method. The rheological data themselves are of great interest for process optimization as
well. The microscopic method allows for a straightforward observation of the physical
state of the materials. However, it is almost impossible to determine the exact solubility
due to resolution limitations. The solubility data can also be determined from the shift of
the glass transition temperature measured via DSC. The DSC method also provides other
valuable information, such as the melting point of the mixture. However, one has to be
careful when using the trend of the glass transition temperature to determine the drug’s
solubility because it is not uncommon for a drug-polymer mixture to have a complicated
and non-monotonic relationship between the Tg and the composition, such as the one at
the 140 ºC case described above.
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4.2 Apparent Room Temperature Solubility Measurements
4.2.1 Estimation of Apparent Drug Solubility at Room Temperature via DSC and
DMTA
Apparent APAP solubility in PEO at room temperature was estimated with similar Tg
evaluation method described in the previous DSC Section 4.1.3. The difference is that
samples were stored at room temperature for four weeks before testing, and the Tg was
determined during the first heating scan. In other words, the Tg value reflects the
mixtures’ physical state at room temperature instead of the state at elevated temperatures.
Glass transition temperatures were determined by using both DSC and Dynamic
Mechanical Thermal Analysis (DMTA) methods. It should be mentioned that the system
has probably not reached thermodynamic equilibrium after four weeks at room
temperature, although the recrystallization does drop to an almost undetectably slow rate
by that time. Hence, the solubility obtained is an “apparent” solubility, which may be
higher than the thermodynamic solubility. In real application though, it is required by the
FDA to perform the long-term stability testing in order to examine the shelf-life of any
pharmaceutical products. Therefore, the experimentally measured “apparent” solubility at
room temperature can provide sufficient information.
DMTA is a thermo-analytical technique. While DSC detects the change in heat
capacity when a polymer changes from the glassy to the rubbery state, DMTA detects the
temperature when a change of modulus occurs. Tg is determined from the peak of the
mechanical loss tanδ, which is responsible for dissipation of energy during deformation
and is defined as:
tan δ = E”/E’

(3.7)
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where E’ is the elastic modulus and represents how much energy the polymer stores, and
E” is the viscous modulus and indicates the polymer’s ability to dissipate energy as heat.
These moduli relate to the stiffness of the material and to its damping capacity (energy
dissipation).
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Figure 4.9 DMTA measured elastic modulus (E’), viscous modulus (E”) and tan δ of
PEO.

The peak of the tan δ is the center of the Tg relaxation while in DSC the onset
temperature of the Tg relaxation is usually reported. In such a case the DSC Tg will be
lower than that obtained from DMTA. In addition, a “frequency effect” puts the
mechanical (ca. 1 Hz) Tg higher than that for a DSC measurement (0.0001 Hz).[159] The
DMTA determined Tg of pure PEO is -44.3 ºC (Figure 4.9), while the Tg from the DSC
measurements is -56.6 ºC. Despite of the difference in absolute numbers, both methods
show similar Tg evolution trends with increasing drug concentration. Only one Tg in each
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APAP-PEO sample is observed. For DSC, Tg increases from -51.2 ºC for 1 wt% of APAP
to -38.7 ºC for 10 wt% of APAP and basically remains constant afterwards. DMTA data
show a similar trend: Tg first increases with APAP loading, but then reaches a plateau at
the concentration around 5%. As presented in Figure 4.10, the critical turning point is
around 10% for DSC and 5% for DMTA. More evidence of APAP recrystallization after
the sample is cooled from the HME processing temperature to room temperature will be
presented in the next few sections.
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Figure 4.10 Glass transition temperatures of 4-week old melt-mixed APAP-PEO
samples measured by using DSC (◊) and DMTA (Δ).
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4.2.2 APAP Recrystallization Observed under Scanning Electron Microscopy (SEM)
Freshly made disc samples with APAP ≤ 30% have a light yellow color, the same as pure
PEO processed under the same conditions. However, unlike the pure PEO, the color of
APAP-PEO mixtures (where APAP >10 wt%) will gradually change to milky white at
room temperature, suggesting the occurrence of APAP’s recrystallization after
processing. The rate of the color change is dependent on the APAP concentration: the
appearance of 20-60% APAP-PEO changes appreciably within several hours, whereas it
takes several days for 10%APAP-PEO samples to exhibit appreciable visual changes.
SEM photos reveal what happens at the micro scale. Freshly made 10%APAP-PEO has a
relatively smooth and APAP particle-free surface (Figure 4.11a). On the contrary, drug
particles, about 1-3 µm in size, are found on the surfaces of 20%APAP-PEO (Figure
4.11b-c) after the same storage time. SEM images of cryo-fractured surface samples
suggest that APAP also recrystallizes at the interior bulk of all samples (Figure 4.12). It
should be mentioned that after 18 days of storage, drug particles appear also at the
surface of 10%APAP-PEO (Figure 4.13). The size of the recrystallized APAP particles
does not change over time (Figure 4.14).
The recrystallization of APAP from a solid dispersion or solid solution formed at
the processing temperature following quenching occurs in two stages as indicated by the
recrystallization rate. For samples with APAP concentration > 20%, the first stage takes
only several hours, whereas for 10%APAP-PEO, the first stage takes weeks. After the
first stage, the systems still have not reached thermodynamic equilibrium. Furthermore,
the recrystallization rate drops significantly in the second stage.
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Figure 4.11 SEM images of freshly-made samples (3 hours after melt mixing) (a)
10%APAP-PEO; (b) 20%APAP-PEO; (c) 20%APAP-PEO.

a

b

Figure 4.12
SEM images of cryo-fractured samples: (a) 20%APAP-PEO; (b)
30%APAP-PEO.
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Figure 4.13 SEM images of 10%APAP-PEO after being stored for 18 days.

a

b

c

5 µm
Figure 4.14 SEM images of the surface of (a) 10% (b) 20% and (c) 30%APAP-PEO
after being stored for 6 months.
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The morphology of the recrystallized APAP particles is of great importance since
it may affect the drug’s dissolution rate in an aqueous medium. For the APAP-PEO
system cooled at room temperature, APAP crystalline particles formed from the
recrystallization process have identical morphologies among samples with different drug
loadings. The APAP particles are several micrometers in size and are richer in
concentration at the sample surface (Figure 4.11c) than in the bulk (Figure 4.12a).
Recently, other research groups have observed similar phenomena in that the
recrystallization tends to happen at the material surface rather than in the bulk.[160, 161]
Firstly, Wei et al. found that the surface tension of high density polyethylene, a semicrystalline polymer, drops a stunning 20% in a small temperature region below the
melting point.[160] They brought up a hypothesis that the initial small crystal regions
would act as nanoparticles and locate at the polymer surface and reduce the surface
tension. The hypothesis was later supported by the results of the statistical modeling of
Thompson et al.[162] Their results showed that the nanoparticles locate robustly at the
polymer surface, that is, the probability of finding a nanoparticle in the vicinity of the
polymer surface is higher than the probability of finding a particle in the bulk. Zhu et al.
found that the crystal growth at the surface of amorphous griseofulvin, a small molecule
drug, to be 10- to 100-fold faster than that in the bulk, and they suggested the cause to be
the molecules at the free surface having higher mobility than bulk molecules.[161]
The APAP loading does not affect the morphology of drug particles formed
during recrystallization. The cooling rate is another parameter that may affect the
morphology of recrystallized drug particles. To investigate the effect of the cooling rate
on recrystallization, 20%APAP-PEO samples were cooled in two different cooling
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media:

open air (slow cooling) and liquid nitrogen (rapid quenching). Figure 4.15

suggests that different cooling rates lead to different morphologies of recrystallized drug
particles. Dispersed drug particles, of several microns in size, are generated in the slowlycooled samples. On the other hand, for the quenched sample, drug molecules grow into
interconnected snowflake-like structures. The morphological difference may be traced to
the different nucleation and growth rates of crystallization. The results suggest that the
cooling rate does affect the drug particle morphologies and needs to be carefully
considered in practice. In some drug-polymer systems, an extremely fast cooling rate may
slow down the molecular mobility so much that the recrystallization becomes almost
undetectably slow. Apparently this is not the case for the APAP-PEO system, a fact
which may be due to the extremely low glass transition temperature of PEO (-56.6 oC).

Figure 4.15 SEM images of 20%APAP-PEO cooled in different media: (a) Air and (b)
Liquid N2.

APAP recrystallization also happens in APAP-nanoclay-PEO ternary mixtures
and the recrystallized APAP is of the same size range as in APAP-PEO binary mixtures
(Figure 4.16). It is unknown at this point whether the ternary system forms a
microcomposite, an intercalated nanocomposite, or an exfoliated nanocomposite due to
the lack of characterization instruments such as small angle X-ray scattering (SAXS) and
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transmission electron microscope (TEM). It is suspected that a microcomposite was
formed since no significant change was observed in the X-ray diffraction (XRD) results
as shown in Figure 4.17. TEM is often used to detect the size of the clay particles and the
silica layers (Figure 2.18 and 2.19). It is difficult for SEM to perform the same duty and
that is the reason why the morphologies of APAP-PEO and APAP-nanoclay-PEO show
little difference.
In summary, SEM results are consistent with the DSC and DMTA results that
above 10%, APAP will recrystallize from PEO. Thus, from a recrystallization point of
view, the results indicate a maximum room temperature solubility of APAP in PEO of
10%. The size and the shape of the recrystallized APAP particles are independent of the
drug loading. However, the cooling rate does affect the drug particles’ morphology to
some extent.
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a
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d

f

5 µm
Figure 4.16 SEM images of the surface of (a)10%APAP-10%Cloisite15A (b)
10%APAP-10%Cloisite30B (c) 20%APAP-10%Cloisite15A (d) 20%APAP10%Cloisite30B (e) 30%APAP-10%Cloisite15A and (f) 30%APAP-10%Cloisite30BPEO ternary mixtures after being stored for 6 months.
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4.2.3 Detection of Recrystallization via X-ray Diffraction (XRD)
Samples with 20 and 30 wt% APAP share the same XRD patterns. Figure 4.17 shows the
XRD spectra of the binary and ternary APAP-PEO mixtures with 30% drug loading. The
solid state of APAP has been intensively investigated.[112, 163] In this study, APAP exists
in monoclinic form in all samples. Consistent with the SEM observations, APAP quickly
recrystallizes within the first day of storage, after which the recrystallization becomes
extremely slow, supporting the results discussed above on the second stage of
recrystallization. APAP crystalline peaks in samples with 10 wt% APAP, on the other
hand, are very weak and it is difficult to draw any conclusions regarding the
recrystallization rate (spectra not shown). This, despite the fact that there is evidence of
very slow recrystallization at that concentration, may be related to the sensitivity of the
XRD. The detection limit of XRD is about 5% of crystalline material.
Adding nanoclays into the APAP-PEO mixture dramatically accelerates the
recrystallization process of APAP (Figure 4.17b-c). Among all the modified Cloisite®
series nanoclays, Cloisite® 15A is the most hydrophobic and Cloisite® 30B the most
hydrophilic (Figure 2.15). Cloisite® 15A is often found to form intercalation
nanocomposites (Figure 2.18) while Cloisite® 30B forms exfoliated nanocomposites
(Figure 2.21). However, the hydrophobicity and structural difference do not appear to
play a significant role since the nanoclays have essentially an identical effect on the
APAP’s recrystallization. Nanoclay particles act as nucleation agents and allow the
APAP recrystallization process to complete within a much shorter time. No further
change in APAP’s solid state is observed during the next sixty days, based on the results
from XRD and SEM. The finding suggests that nanoclays can potentially be employed to
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prepare more stable tablets at the concentration which is dictated by the ambient
temperature solubility.
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Figure 4.17 XRD spectra of (a) 30%APAP; (b) 30%APAP10%Cloisite15A and (c)
30%APAP10%Cloisite30B-PEO.
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It should be mentioned that nanoclays can also affect the polymer’s crystallization
rate to various degrees, depending on the polymer-nanoclay system. For example, the
addition of silicate layers can induce hetero-phase nucleation and promote the growth of
polyamide crystallites.[164] Another study has shown that the crystallization kinetics of
polyamide nanocomposites increase only when clay concentrations are very low, while
high clay loadings retard the crystallization by restricting lamellae coarsening in PEO.[165]
The clay particles act as a nucleating agent for maleic anhydride grafted polypropylene,
but do not influence the linear growth rate of spherulites or overall crystallization rate
significantly. [166] The APAP-nanoclay-PEO is a more complicated system comprising
several phases, including layered silicate, amorphous APAP and PEO regions, crystalline
PEO regions and crystalline APAP regions.

4.3 Room Temperature Solubility Prediction using the Flory-Huggins Theory
4.3.1 Theoretical Background
This section of the thesis work aims at the theoretical prediction of the drug’s solubility
in the polymer excipient and, especially, the understanding of the material parameters
that influence the solubility. The polymer is regarded as a viscous solvent and the
solubility of a solid drug in a polymer is described by the mixture phase equilibrium
equation[167] below.
ln x1a1 = −

∆ fus H
RT

[1 −

T
1
]−
Tm
RT

∫

T

Tm

∆C p dT +

1 T ∆C p
dT
R ∫Tm T

(4.3)

Here, x1 is the saturation mole fraction of a solid drug in the polymer, a1 is the
activity coefficient of the drug in the polymer at the solubility limit, Tm is the drug’s
melting temperature, T is the designated temperature of interest (300 K, i.e., room
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temperature, in the current study), ∆fusH is the drug’s heat of fusion at the melting point,
R is the universal gas constant, and ∆Cp is the heat capacity difference between solid and
liquid drug ( ∆C p = C pL − C pS ). Herein, liquid drug refers to the amorphous drug. ∆Cp is a
function of temperature and the data can be found in the early literature.[11] Considering
that ∆Cp does not change significantly in the temperature range of interest, it is assumed
to be constant and Equation (4.3) can be rewritten as Equation (4.4).
ln x1a1 = −

∆ fus H
RT

[1 −

∆C p
T
T
T
]−
[1 − m + ln( m )]
Tm
R
T
T

(4.4)

It is necessary to know the activity coefficient a1 in order to calculate the molar
solubility x1. Based on the Flory-Huggins lattice theory, the activity coefficient of APAP
is given by Equation (4.5).

ln a1 = ln

φ1
x1

+ (1 −

1
)φ 2 + χφ 22
m

(4.5)

Here, φ1 is the volume fraction of the drug, φ2 is the volume fraction of the
polymer, m is the molar volume ratio of a polymer molecule to a drug molecule, and χ is
the Flory-Huggins interaction parameter. Assuming the molar volume of the repeating
unit in PEO is equal to the molar volume of APAP, that is, a drug molecule (○) occupies
the same size of the grid as a segment of a polymer (●) does as in Figure 1.14,
relationships between φ1 , φ 2 and x1 are expressed by Equation (4.6)

φ1 =

x1
m(1 − x1 )
and φ 2 =
x1 + m(1 − x1 )
x1 + m(1 − x1 )

(4.6)

The drug’s solubility at a specific temperature can be calculated using Equations
(4.3-4.5) when the value of χ is known. The interaction parameter χ can be calculated
from melting point depression experiments, which have been widely applied to study
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polymeric mixtures.[168-170] Similarly, the melting point of the drug in the presence of
polymer can be described using Equation (4.7):

1
mix
m

T

−

−R
1
1
=
[ln φ1 + (1 − )φ 2 + χφ 22 ]
Tm ∆ fus H
m

(4.7)

Tm is the melting point of the pure drug, while Tmmix is the melting point of the
drug mixed with a polymer. The values of Tmmix at different compositions have been
determined from high temperature solubility measurements previously, thereby the
interaction parameter χ can be obtained by fitting [ (

1
mix
m

T

−

1 ∆ fus H
1
)
− ln φ1 − (1 − )φ 2 ]
Tm − R
m

linearly with φ22 .

4.3.2 Theoretical Calculation of APAP’s Solubility in PEO
Figure 4.18 is a replot of Figure 4.8 showing the melting points of APAP at different
polymer concentrations. It is worthwhile to point out that these APAP-PEO samples were
melt-mixed using a Brabender mixer. As a result, the size of the undissolved dispersed
APAP phase (Figure 4.14) becomes much smaller than the size of the original drug
particles (Figure 2.5), which allows the sample to reach equilibrium much faster during
heating in DSC. In other words, a faster heating rate, as compared to the typical slow
scanning rate needed for Tmmix determination,[70-73] can be used. Increasing the scanning
rate not only saves experimental time, but also, more importantly, prevents the drug from
thermal degradation. In this thesis work, a 10 oC/minute heating rate was used in DSC to
determine the Tmmix as explained in Chapter 4.1.3.
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Figure 4.18 Melting point of APAP-PEO mixtures Tmmix (□) with different weight
percentage of PEO.

The Tmmix of 86, 80, 69, 59, and 50 PEO wt% are 353, 373, 393, 413 and 432.74
K, respectively. The melting point and ∆fusH values of pure APAP are determined from
DSC and are 446.17 K and 29372.3 J/mol, respectively. The polymer-drug molar volume
ratio m is 757 as calculated below:
molar volume (PEO)
MW/density (PEO) 100,000 g / mol / 1.13 g / cm 3
m=
=
=
= 757
molar volume (APAP) MW/density (APAP) 151.17 g / mol / 1.293 g / cm 3
After
(

1
mix
m

T

−

substituting

all

the

variables

into

Equation

(4.7),

1 ∆ fus H
1
)
− ln φ1 − (1 − )φ 2 values were plotted against φ22 (Figure 4.19). The
Tm − R
m

slope of the linear-fitted curve gives the χ value of -1.65 with R2 of 0.970. The drug’s
solubility at 300 K was calculated from Equations (4.4-4.6) by using χ = -1.65 and ∆Cp =
107 J/(mol· K).[11]
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Figure 4.19 Plot of Equation (4.7) for the APAP-PEO system.

The APAP’s mole solubility x1 is calculated to be 98.9 mol% and the weight
solubility w1 is 11.7 wt% at 300 K. It should be emphasized that 11.7 wt% is the
solubility in the amorphous portion of PEO. It is believed that much less APAP can be
dissolved in crystalline PEO, if there is any, than in its amorphous portion.[171] For
example, gas transport properties in a semi-crystalline polymer such as PEO are usually
modeled by assuming that the crystals act as an impermeable dispersed phase imbedded
in a permeable amorphous phase.[172] Assuming there is no APAP molecule dissolved in
the crystalline regions of PEO, the overall solubility is reduced to 2.3% considering the
fact that the crystallinity of PEO is around 80% for the PEO used, as determined
experimentally using DSC. The apparent solubility after a month at room temperature
was measured to be less than 10% based on previous DSC, DMTA, SEM and XRD
results. Lower calculated theoretical solubility suggests that the system may still have not
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reached equilibrium after one month. Nevertheless, the theoretical and apparent solubility
from experiments are still close. The model was also used to calculate APAP’s solubility
in liquid PEG, which was compared to the obtained experimental data. The results will be
presented in a later section.

4.3.3 Free Energy of Mixing: Entropic and Enthalpic Effects
The Flory-Huggins theory[78,

79]

is a natural extension of regular solution theory for

monomeric liquids to systems involving polymers in the amorphous state. It is a
celebrated and successful molecularly-based model giving a convenient framework for
describing the thermodynamic properties of polymer solutions and molten polymer
mixtures. It represents the volume of a polymer system as a lattice which is divided into
microscopic sites of the same volume (Figure 1.14). In the APAP-PEO system, one drug
molecule is assumed to occupy one site, while a polymer molecule occupies m sites. The
entropy of mixing of a drug-polymer system is smaller than that of a drug-small molecule
system because there are fewer ways in which the same number of lattice sites can be
occupied by polymer segments than by small molecules. In other words, mixing of large
molecules involves smaller entropy of mixing, which is unfavorable for mixing. The free
energy of mixing ∆Gm for a drug-polymer system can be described by Equation (4.8).

∆Gm
= N1 ln φ1 + N 2 ln φ2 + χN1φ2
RT

(4.8)

Here, N1 is the number of moles of the drug, N2 is the number of moles of the
polymer, φ1 is the volume fraction of the drug, φ2 is the volume fraction of the polymer,
R is the universal gas constant and T is the designated temperature of interest. The first
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two terms on the right hand side represent the entropy of mixing, while the third term
stands for the enthalpy of mixing.
To investigate the entropic effect on the free energy of mixing, ∆Gm/RT vs. the
composition at different m values were plotted (χ is fixed at -1.65) in Figure 4.20. The
value m = 757 represents the PEO used, while m values of 48 and 3 are estimated using
PEO’s low molecular weight analog PEGs with MW of 6000 and 400 g/mol,
respectively. The calculation results suggest that ∆Gm/RT varies only slightly with m,
with ∆Gm/RT (m = 757) > ∆Gm/RT (m = 48) > ∆Gm/RT (m = 3). In other words, the
change of ∆Gm is not significant when the MW of the polymer changes from 100,000 to
400 g/mol.
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Figure 4.20 Free energy of mixing ∆Gm/RT vs. weight percentage of polymer as
predicted using the Flory-Huggins theory with different polymer-drug volume ratios m.
Curves from top to bottom are for m = 757 (PEO used), 48 (PEG 6000) and 3 (PEG 400)
(χ = -1.65).

The Flory-Huggins interaction parameter χ characterizes the excess energy of
interaction in solution per one molecule of the solvent. The curves of ∆Gm/RT vs. mixture
composition at different χ value are plotted in Figure 4.21 (m is now fixed at 757). The
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results show that the Gibbs free energy of mixing increase significantly with increasing χ.
∆Gm/RT is even positive in part of the χ = 2 curve, suggesting poor miscibility of drug
and polymer. Negative χ, on the other hand, leads to lower ∆Gm/RT and, consequently,
better miscibility between the drug and polymer. By comparing Figure 4.20 with Figure
4.21, it seems that the polymer-drug interaction parameter plays a more important role in
the polymer-drug miscibility compared to that of the polymer MW. However, it should
be mentioned that the drug’s solubility in the polymer cannot be determined directly from
∆Gm/RT. Thus, a direct calculation of drug’s solubility in polymers of different MW and
χ will be given in a later section.
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Figure 4.21 Free energy of mixing ∆Gm/RT vs. weight percentage of polymer as
predicted using the Flory-Huggins theory with different interaction parameters χ. Curves
from top to bottom are for χ = 2, 0 and -1.65 (m = 757).

4.3.4 Enthalpic and Entropic Effect on the Drug’s Melting Point Depression
As mentioned above, χ is a critical parameter which affects the miscibility of a polymer
and a drug. However, it is difficult to theoretically predict its value. Hence, it is of
interest to find out whether there are any simple experiments that help to compare the
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interaction parameters of a drug with different polymers. Figure 4.22 shows the curves of
the melting temperature of the drug vs. polymer loading at different interaction
parameters based on Equation (4.7), which suggests that the melting point depression is
sensitive to the χ value. In other words, the melting point depression may be used
experimentally for determination of the χ value and use it as a practical indicator for
polymer selection to a given API. Similarly to the impact on ∆Gm/RT, the polymer MW
shows only a small effect on the melting depression (Figure 4.23).
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Figure 4.22 Melting point depression vs. weight percentage of polymer. The temperature
curves are calculated using Equation (4.7) with χ = 2, 0 and -1.65 from top to bottom (m
= 757).
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Figure 4.23 Melting point depression vs. weight percentage of polymer. The temperature
curves are calculated using Equation (4.7) with m= 757 (PEO used), 48 (PEG 6000) and
3 (PEG 400) from top to bottom (χ = -1.65).

4.3.5 Effect of Polymer MW and χ on APAP’s Solubility in PEO/PEG Excipients
Assuming that χ as measured from the melting point depression of APAP in PEO N10
could be extended to estimate the χ in PEG 400 because of the same molecular structure
of the PEO and PEG, the APAP’s solubility in PEG 400 (Mw = 400 g/mol) at 300K was
calculated to be 14.6 wt% by using the same χ of -1.65. The predicted solubility of APAP
in PEO N10 (Mw = 105 g/mol) is less than that in PEG 400, which is caused by the
reduced entropic contribution to the mixing in the PEO N10 system. Therefore, attempts
to estimate the solubility of a drug in a polymer by measuring solubility in a low
molecular weight analogue of the polymer need to be corrected accordingly to avoid
overestimating the solubility.[73] The analysis specifies how to avoid this.
In an attempt to verify the validity of this method, the solubility of APAP was
measured in liquid PEG 400 and the result was 17.1%. Thus, the theoretical and
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experimental solubilities are close, suggesting that the χ value calculated from the
melting point depression method is a reasonable estimate.
To understand the broader impact of χ, which is represented by the polymer
chemistry, and polymer MW on the drug’s solubility, the drug’s solubilities at different χ
and m values were calculated and are given in Table 4.2. The χ values used here are from
drug-polymer pairs, including indomethacin-PVP (χ = -1.83), nifedipine-PVP (χ = -0.81),
and ketoconazole-PVP (χ = -0.12).[71] The results show that the solubility decreases by an
order of magnitude when χ increases from -1.83 to -0.12, while the very low MW
polymer (MW=400) only leads to 24-36% higher drug solubility as compared to large
MW analogue (MW=100,000). It should be noted that process requirements often limit
the usage of the MW of polymer excipients. Low MW PEG in this case is a liquid and
cannot be used as the major excipient for solid dosage, while extremely high MW may
cause difficulty for processing due to high viscosity. Hence, one should focus on the APIpolymer excipient intermolecular interactions rather than the polymer MW to improve
drug-polymer miscibility.

Table 4.2 Solubility in Drug-polymer Pairs Calculated Using Various Flory-Huggins
Interaction Parameters χ at Different Polymer MW
χ
wt% in large MW
polymer (m=757)
wt% in small MW
polymer (m=3)

-1.83

-1.65

-0.81

-0.12

13.1

11.7

6.2

3.3

16.2

14.6

8.2

4.5
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4.4 Dissolution Testing
The experimentally obtained dissolution rates of APAP-PEO and APAP-nanoclay-PEO
are much slower than that of pure APAP powder in a capsule, as shown in Figures 4.244.26. It takes less than 30 minutes for powder-form APAP to be fully released into the
buffer solution, while it takes melt-mixed APAP-PEO 90 minutes and APAP-nanoclayPEO more than 360 minutes, an order of magnitude slower than powder form APAP, to
be fully dissolved. Thus, the hot-melt mixed APAP-PEO samples are controlled-release
formulations. The standard deviation for each release curve was less than 5% and
therefore, is not shown.
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Figure 4.24 Dissolution profiles of (×) APAP powder in capsule, (▲) 10%APAP-PEOday 1, (Δ) 10%APAP-PEO-day 169, (♦) 10%APAP-10%CL15A-PEO-hour 1, (◊)
10%APAP-10%CL15A-PEO-day 251, (■) 10%APAP-10%CL30B-PEO-hour 1, (□)
10%APAP-10%CL30B-PEO-day 251.
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Figure 4.25 Dissolution profiles of (×) APAP powder in capsule, (▲) 20%APAP-PEOhour 1, (Δ) 20%APAP-PEO-day 160, (♦) 20%APAP-10%CL15A-PEO-hour 1, (◊)
20%APAP-10%CL15A-PEO-day 212, (■) 20%APAP-10%CL30B-PEO-hour 1, (□)
20%APAP-10%CL30B-PEO-day 212.
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Figure 4.26 Dissolution profiles of (×) APAP powder in capsule, ( ) 30%APAP-PEOhour 1, (Δ) 30%APAP-PEO-day 148, ( ) 30%APAP-10%CL15A-PEO-hour 1, (◊)
30%APAP-10%CL15A-PEO-day 213, ( ) 30%APAP-10%CL30B-PEO-hour 1, (□)
30%APAP-10%CL30B-PEO-day 213.
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Storage time shows little impact on the dissolution rate (Figures 4.24-26). For
example, the Figure shows that the drug release profile on day 1 is essentially the same as
that on day 169 for sample 10%APAP-PEO. A couple of facts should be mentioned in
discussing this observation: firstly, in all cases, APAP particles never grow into more
than several micrometers in size. In other words, the morphology does not change with
the storage time. Secondly, PEO does not dissolve quickly but swells into a gel in the
aqueous medium. Subsequently, the gel gradually dissolves and by the time it disappears,
the drug is fully released. The slow dissolution rate of PEO may thus overshadow any
changes in the APAP’s dissolution rate during storage.
Diffusion, swelling and erosion are the most important rate-controlling
mechanisms of commercially available controlled-release products.[173] In order to
understand the mode of drug release from PEO matrices, the data (Mt/M∞) are fitted
using the following power law expression:[174-177]

Mt
= kt n '
M∞

(4.9)

Mt, M∞, k and n’ are, respectively, the amounts of drug released at time t, the
absolute cumulative amount of drug released at infinite time, a constant incorporating the
structural and geometric characteristics of the release device, and the exponent of the
release kinetics. This semi-empirical equation was used to analyze the first 60% of a
release curve (Mt/M∞ ≤ 60%). The values of n’ were obtained by fitting drug release data
to Equation (4.9) using the ordinary least square regression (values ± 95% confidence
limits) provided by software Polymath 5.1 (Polymath software, Willimantic, CT). It is
widely accepted that for a disc, n’ = 0.5 suggests a diffusion-controlled release
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mechanism and, zero order drug release (n’ = 1.0) indicates an erosion-controlled release
mechanism. Anomalous transport leads to a value between 0.5 and 1.[175, 178]
Table 4.3 Fitting Results for Equations (4.9) and (4.10). In All Cases R2 Is Greater Than
0.99
Sample

[174-177]

Power Law

Peppas and Sahlin

Mt
= kt n '
M∞
n' ± 95% CI

[179, 180]

Mt
= k1t 0.5 + k 2 t
M∞
k1 (% min-0.5) ± 95%
CI

k2 (% min-1) ± 95% CI

10%APAP-PEO-day 1

1.02 ± 0.01

-0.16 ± 0.29

1.01 ± 0.05

20%APAP-PEO-hour 1

0.89 ± 0.06

1.40 ± 1.11

1.25 ± 0.21

30%APAP-PEO-hour 1

0.89 ± 0.03

1.57 ± 0.61

1.26 ± 0.12

10%APAP-10%CL15A-

0.71 ± 0.02

2.13 ± 0.26

0.21 ± 0.03

0.56 ± 0.03

4.16 ± 0.29

0.07 ± 0.03

0.70 ± 0.01

2.63 ± 0.37

0.21 ± 0.04

0.67 ± 0.03

3.66 ± 0.61

0.21 ± 0.07

0.71 ± 0.01

2.44 ± 0.24

0.22 ± 0.02

0.72 ± 0.02

2.63 ± 0.47

0.23 ± 0.05

0.68 ± 0.01

3.02 ± 0.42

0.24 ± 0.05

0.71 ± 0.02

2.52 ± 0.42

0.25 ± 0.05

0.69 ± 0.06

3.52 ± 1.07

0.33 ± 0.14

PEO-hour 1
10%APAP-10%CL15APEO-day 251
10%APAP-10%CL30BPEO-hour 1
20%APAP-10%CL15APEO-hour 1
20%APAP-10%CL15APEO-day 212
20%APAP-10%CL30BPEO-hour 1
30%APAP-10%CL15APEO-hour 1
30%APAP-10%CL15APEO-day 213
30%APAP-10%CL30BPEO-hour 1
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The values of n’ for APAP release are listed in Table 4.3. It is interesting that the
exponent n’ decreases from 1 for APAP-PEO system to about 0.7 for the APAPnanoclay-PEO mixtures, indicating that drug release shifts from erosion dominant to
anomalous by the addition of nanoclays.
Another power-law based expression developed by Peppas and Sahlin[179, 180] is
Equation (4.10) and it can be used to estimate the contributions of drug diffusion and
polymer erosion to the anomalous release.

Mt
= k1t m ' + k 2 t 2m '
M∞

(4.10)

The first term on the right hand side represents the contribution of drug diffusion
and the second term the contribution of polymer erosion. The coefficient m’ is the
diffusion exponent for a controlled release device of any geometrical shape exhibiting
pure drug diffusion. The value of m’ for the disc (or film) is 0.5 according to Peppas and
Sahlin. Drug release data are fitted to Equation (4.10) using the software Polymath 5.1. k1
and k2 are the diffusion and relaxation constants, respectively.
The results show that the APAP diffusion has a much higher contribution to
dissolution than polymer erosion (k1 >> k2) (Table 4.3) for the ternary mixtures. The
difference in drug release mode between the binary and ternary mixtures is postulated to
be caused by the decrease of wettability with the presence of nanoclays. It should be
noted that the nanoclays are modified by the suppliers to improve their compatibility with
polymers. The modified clays are more hydrophobic than the original montmorillonite.
On the other hand, the contact angle of dissolution medium on the surface of 10%APAPPEO is found to be 41º, ten degrees smaller than that on the surface of 10%APAP10%CL15A-PEO or 10%APAP-10%CL30B-PEO. The decrease in wettability brought
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by the presence of Cloisite® clays dramatically slows down the dissolution rate of the
matrix: for the APAP-PEO system, the full release of APAP and the complete dissolution
of matrix occur at the same time, roughly one hour since the sample was immersed in the
solution. In comparison, the matrix of the ternary mixture remains intact even after six
hours, when all APAP has been released.

4.5 Crystallization of PEO and APAP-PEO
4.5.1 Theoretical Background
4.5.1.1 Nucleation and Growth Kinetics Theories.

Spherulitic nucleation

and growth kinetics can be analyzed using the kinetic nucleation theory expounded by
Hoffman et al.[181-185] Three regimes for nucleation and crystal growth are predicted by
this theory caused by different degrees of supercooling. They are represented by the
schematic drawings in Figure 4.27.[183, 184] In the Figure, G is the growth rate, L is the
substrate length, b0 is the thickness of the molecular layer, and a0 is the stem width. The
kinetics in each regime are being controlled by the competition between nucleation and
growth. In regime I, a single nucleation site takes place on the substrate surface and leads
to the substrate length being completely covered by a crystallization growth layer. At a
lower temperature (i.e., higher supercooling, ∆T), regime II growth prevails where
multiple nucleation sites take place on the substrate. At still larger supercooling ∆T,
regime III is entered where nucleation on the substrate is so prolific that the distances
between niches sites (Sn in Figure 4.27b) approximate a stem width. An example of three
regime experimental crystal growth kinetics is presented in Figure 4.28, which shows
growth rate data of polyethylene.[186]
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Figure 4.27 Schematic representation of how polymer crystal growth takes place in three
regimes: (a) regime (I); (b) regime (II); (c) regime (III) occurring at increasing degree of
supercooling.[183, 184]
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MW 70300

Figure 4.28 Experimentally measured linear crystal growth rate of polyethylene
crystallized from the melt.[186]

For each of these regimes, the crystal growth rate is expressed by the following
expression based on the Hoffman-Lauritzen (HL) model:
− K g (i )
−U *
G (i ) = G 0 (∆T ) exp(
) exp(
)
R (Tc − T∞ )
Tc ∆Tf

(4.11)

where i = I, II or III denotes regimes, ∆T is the degree of supercooling ( Tm0 – Tc) with Tm0
being the equilibrium melting temperature and Tc being the crystallization temperature,
U * is the activation energy needed for “reeling in” the polymer molecules (defined

below) from their melt reptation tube,[187] R is the universal gas constant, T∞ is the
temperature below which this type of chain transport ceases (taken as Tg – 30 K), and f is
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a temperature correction factor accounting for the change of melting enthalpy with
temperature, given by 2Tc/( Tm0 +Tc). The pre-exponential term G0 contains terms that are
essentially temperature-independent. Each regime has a nucleation constant Kg(i), and
Kg(I) = 2 Kg(II) = Kg(III) with

4a 0σσ eTm0
K g ( I) =
∆H f k

(4.12)

where σ is the lateral surface free energy, σe is the lamellar fold surface free energy which
is related to the difficulty of the chain to perform folding during crystallization, a0 is the
stem width (the lattice distance between adjacent planes) as shown in Figure 4. 27, k is
the Boltzmann constant, and ∆Hf is the heat of fusion per crystal unit volume.
Taking the logarithm of Equation (4.11) and rearranging, one obtains
Kg
U*
ln G − ln( ∆T ) +
= ln G0 −
R (Tc − T∞ )
fTc ∆T

(4.13)

Kovacs et al.[188-192] have quoted a value of 29.3 kJ/mol for U* while Hoffman et
al.[181] have suggested that U* has a universal value of 6.28 kJ/mol. Cheng et al. have tried
both values for PEO and they preferred the former, [92] and consequently this value is here.
The glass transition temperature Tgs of PEO, 2%, 10% and 20%APAP-PEO are -56.6, 45.9, -27.5 and -16.2 ºC, respectively. The equilibrium melting temperature Tm0 of a
polymer crystal is defined as the melting temperature of an “infinite stack” of extended
chain crystals, large in directions perpendicular to the chain axis and where the chain
ends have established an equilibrium state of pairing.[193] This quantity is one of the most
important thermodynamic properties of crystallizable chain polymers, as it is the
reference temperature from which the driving force for crystallization is defined. Tm0 is
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determined by extrapolation to the condition of Tm = Tc according to the Hoffman-Weeks
(HW) equation[194]

Tm =

1
1
Tc + (1 − )Tm0
γ'
γ'

(4.14)

where γ’ is the lamellar thickness factor, which is the ratio of the lamellar thickness to the
critical nucleus thickness in the crystallization process. The HW equation is based on the
assumption that the difference between crystallization and observed melting temperatures
is solely due to the thickening of lamellae formed at the crystallization temperature.
Because of its straightforward experimental implementation and its analytical simplicity,
this method has been widely and successfully used for the determination of Tm0 of semicrystalline polymers.[193, 195-197]

4.5.1.2 Macroscopic Crystallization Kinetics (Avrami Theory).

The celebrated

Avrami analysis of isothermal crystallization kinetics was originally developed for
metals[198-201] and later modified by others, for example, by Evans[202], for polymers. The
resultant equation is
1 - X(t) = exp(-Kntn)

(4.15)

where Kn is the overall rate constant for the crystallization process, n is the Avrami
exponent and X(t) is the crystallinity of the polymer at time t and is calculated from DSC
isothermal exotherms as
X (t ) =

∆ fus H t
∆ fus H ∞

(4.16)

where ∆fusH∞ and ∆fusHt are the enthalpies of fusion on complete crystallization and at
time t. n depends on the morphology of the growing crystalline regions, the nucleation
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process, and whether growth is controlled by diffusion of polymer through the melt or by
attachment to the growth surface. Based on Shultz’s summary on the consequence of the
Avrami theory (Table 4.4),[203, 204] the case n = 4 can only result from spherulitic growth
from homogeneous nucleation. The analysis involves plotting log[-ln(1-X(t)] as a
function of log t and determining n from the initial slope and Kn from the intercept.

Table 4.4 Interpretation of Avrami Coefficients[204]
Avrami Exponent
½
1
1
3/2

2
5/2
3
4

Nucleation Type
Instantaneous
Instantaneous
Instantaneous
Instantaneous
Homogeneous
Instantaneous
Homogeneous
Homogeneous
Homogeneous
Instantaneous
Homogeneous
Homogeneous

Growth Geometry
Rod
Rod
Disc
Sphere
Rod
Disc
Disc
Rod
Sphere
Sphere
Disc
Sphere

Growth Velocity
t-1/2
Constant
t-1/2
t-1/2
t-1/2
Constant
t-1/2
Constant
t-1/2
Constant
Constant
Constant

4.5.2 Equilibrium Melting Temperature
The HW equation was used to determine the Tm0 s of pure PEO as well as the APAP-PEO
mixtures prepared by solvent evaporation. The observed melting temperatures, Tm from
the DSC 2nd heating are plotted against different crystallization temperatures Tc and
shown in Figure 4.29. The values of 1/γ’, which are the slopes of the resulting linear
curves, are 0.17, 0.18, 0.26, 0.20, 0.39, and 0.52 for PEO, 0.1%, 1%, 2%, 10% and
20%APAP-PEO, respectively. The value of 1/γ’ is between 0 (Tm = Tm0 for all Tcs, the
most stable crystal morphology) to 1 (Tm = Tc, for the case of inherently unstable
crystals). The results show that the stability of the PEO crystals decreases dramatically
with increasing APAP concentration. The equilibrium melting temperature Tm0 also
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increases with APAP concentration, from 67.1 oC of PEO to 68.0, 69.6, 69.3, 73.0 and
78.1 oC for 0.1%, 1%, 2%, 10% and 20%APAP-PEO, respectively. The shifting trend of
Tm0 is the opposite to that of the miscible polymer blends where Tm0 decreases with
increasing amount of the second polymer.[94, 205, 206] It is also possible that APAP, whose
Tm is 170 oC, starts to recrystallize during the process and contributes to the Tm0 increase.

365
Melting Temperature Tm (K)

a

PEO
0.1%APAP
1%APAP

355

2%APAP
10%APAP
20%APAP

345

b

335
Tm = Tc
325
300

b

310

320 330 340 350 360 370
Crystallization Temperature Tc (K)

340

Melting Temperature Tm (K)

PEO
0.1%APAP

338

1%APAP

336

2%APAP
10%APAP

334

20%APAP

332
330
328
308

312
316
320
324
Crystallization Temperature Tc (K)

328

Figure 4.29 Hoffman-Weeks plots for PEO, 0.1%, 1%, 2%, 10% and 20%APAP-PEO.
(b) is the zoom in of the rectangle area of (a).
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4.5.3 Polarized Optical Microscopy (POM)
PEO, 0.1%, 1% and 10%APAP-PEO have spherulitic morphologies as evidenced by the
Maltese cross patterns at Tx of 30 oC in Figure 4.30 below. As Tx increases and the
supercooling ΔT decreases (Txs of 40 and 50 oC), more amorphous content is formed in
the crystals, which makes the texture more open and the Maltese cross patterns weaker.
Similar phenomena were observed by previous investigations for PEO (MW = 10,500
g/mol)[92] and PEO (MW = 1,000 g/mol).[207] Figure 4.31 demonstrates the increasing
“open” texture and weakening Maltese cross patterns of PEO with increasing
crystallization temperature.[92] The apparent complete destruction of spherulite structure
for 10%APAP-PEO at 50 oC is caused by either inclusion or exclusion of the APAP
defects, which will discussed in details later.
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Figure 4.30 Polarized optical micrographs of spherulites at Tx of 30, 40 and 50 oC for
PEO, 0.1%, 1% and 10% APAP-PEO. The POM field of view in pictures with 500 µm
scale bar is a circle with diameter of 2.4 mm.
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Figure 4.31 The spherulite morphology of PEO (MW 105,000) at different degrees of
supercooling in the vicinities of regime transitions: (a) ΔT= 18.5K; (b) ΔT=16.5K; (c)
ΔT=11 K; and (d) ΔT=9.5 K.[92]

It is seen from Figure 4.30 that the number of spherulitic nuclei in the 10%APAPPEO mixture at Tx of 30 oC is substantially higher than that in the pure PEO, 0.1% and
1% APAP-PEO. The detailed results are summarized in Figure 4.32. At Tx of 30 oC, the
number of nuclei in the 10%APAP-PEO samples is five times of that in PEO, indicating
that APAP functions as a nucleating agent, denoting the existence/presence of tiny APAP
crystalline regions, that reduce the free energy required to build new surfaces during
crystallization. The results strongly suggest that APAP either recrystallizes or forms
amorphous nanosize clusters[155] because it is oversaturated in the PEO at 30 oC. At Tx of
50 oC, the number of nuclei is the same for all samples regardless of the APAP
concentration, suggesting that at this temperature, APAP and PEO are fully miscible. It
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seems that 9% of APAP is dissolved when the temperature is raised from 30 to 40 oC,
since the number of nuclei for 10%APAP-PEO and 1%APAP-PEO is the same. The fact
that 1%APAP-PEO had more nuclei than PEO did at 40 oC hinted that the solubility was
less than 1%. The reason for 1%APAP-PEO to have the same amount of nuclei as PEO at
30 oC was possibly due to the low molecular mobility at that temperature so that APAP
did not recrystallize even though the solubility limit was exceeded. Based on these
results, amorphous APAP could exist in the crystalline portion of PEO, possibly at a
concentration between 0.1 and 1% at 30 oC.
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Figure 4.32 Number of nuclei in the POM field of view (a 4.5 mm2 area) of PEO and
APAP-PEO mixtures at different Tx.
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Under isothermal crystallization conditions, spherulitic growth rates were
calculated from the slope of the spherulite diameter versus time plots. The results
obtained show a good linear increase of spherulite diameter with crystallization time for
all samples. The spherulitic growth rate G is found to decrease with increasing APAP
content as shown in Figure 4.33. The decrease is appreciable only for the 10%APAP
concentration sample, where APAP solid regions are suspected to exist. When a polymer
contains “defects”, APAP in this case, these defects must be rejected from the crystals as
long as they are sizable and cannot be accommodated by the lamellar folded chain
growing crystallization regions.[208] Only small size defects may be included in the
crystals. Thermodynamic descriptions of defect exclusion[209] and inclusion[210] in the
crystal have been proposed. There are many case examples of steric reasons for
exclusion[211-214] (short-chain branches formed by the comonomers of 1-butane, 1-hexane,
or 1-octane in i-PP copolymers) as well as inclusion[215-217] (stereo-defect in i-PP) in the
literature papers. Figure 4.34 shows the growth rate data for a series of i-PP with different
isotacticities. With decreasing isotacticies, the growth rates are significantly reduced,
while the structural analysis (small angle X-ray scattering and transmission electron
microscopy, which will be discussed in more details later) indicates that the stero-defects
of i-PP are included in the crystals.[216] In summary, both exclusion and inclusion
mechanisms can slow down the growth rates as observed in the APAP-PEO system used
in this work.
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Figure 4.33 Isothermal spherulitic growth rate G (µm/s) of PEO and APAP-PEO at
different Tx.

Figure 4.34 A set of linear growth rates of i-PP having five different extents of
isotacticities over a wide crystallization temperature Tc range. From top to bottom,
isotacticities of 98.8% PP(X-20), 97.8% PP(Y-17), 95.3% PP(Y-9), 88.2% PP(X-6) and
78.7%PP (X-3), respectively.[216]
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For the case of a melt-miscible polymer blend of a semi-crystalline and an
amorphous polymer, the length scale over which the diluent polymer diffuses during
crystallization is determined by the relationship between the diffusion coefficient of the
amorphous polymer in the semi-crystalline polymer and the crystallization rate.[218-221]
The diluent polymer can reside in interlamellar regions (amorphous layers between
crystalline lamellae), interfibrillar regions (amorphous regions between stacks of
lamellae) and interspherulitic regions,[219] and the resulting segregation mechanisms are
schematically illustrated in Figure 4.35. The difference between small molecular weight
drugs and amorphous polymers is that the former, because of their size, are more
favorable to be confined within the interlamellar regions, or even within the intralamellar
regions. Having said this, the physical state of APAP is nevertheless unclear at this point.
It might exist as amorphous clusters,[155] crystalline particles with the unit cell dimension
of a monoclinic crystal being approximately 7.1 Å× 9.4 Å× 11.7 Å× sin(97.4o) (0.77
nm3),[111] or single molecules. Recently, Shekunov et al. reported that in the polymer
synthesized from PEO crosslinked by polyurethane (PEO-PU), a hydrogel system, APAP
was able to shift the SAXS peak (Figure 4.36) while the other model drug caffeine was
not.[155] The reason for the difference is because APAP can form strong hydrogen bonds
with the PEO, leading to a PEO-APAP complex, while the intermolecular interactions
between caffeine and PEO-PU are much weaker and therefore their effect on the polymer
structure is less pronounced. The size of APAP, derived from SAXS, was estimated to be
between 7-10 nm.
At Tx of 30 oC when both PEO chain folding and APAP recrystallization rates are
fast, the APAP may only affect the nucleation sites but not the isotropic three-dimensional
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a.

Interlamellar

b. Interfibrillar

c. Interspherulitic

d. Intralamellar

Figure 4.35 Possible modes of segregation in a binary blend that is miscible in the
amorphous state and contains one crystallizing component, (a-c) adapted from the
literature paper;[219] (d) was proposed by the author, ● APAP.

shape or Maltese pattern. POM images show that the spherulites are space-filled with no
evidence of APAP interspherulitic accumulation even for 10%APAP-PEO (Figure 4.37).
At Tx of 50 oC, however, the morphology of 10%APAP-PEO is more dendritic than
spherulitic with large unfilled space in between spherulites. To determine if APAP is
located in the interspherulitic regions, one may use micro-Infrared (IR) spectroscopy
coupled with POM for determination. The POM locates the microprobe to the area for IR
measuring, the dark unfilled space in Figure 4.37 (b) for example, and the IR will
determine if APAP exists in that particular space. The physical state of the APAP can
also be determined by comparing the peak positions in the IR spectra.[32]
Since typical polymers are about 1000 nm long and the lamellar thickness is
around 10 nm,[23] it is possible for APAP to locate either in the intralamellar,
internlamellar, interfibrillar, or all these three regions. The most commonly used
characterization techniques to determine the additive’s location are SAXS and TEM.
Recently, Zhu et al. have used SAXS to detect the increase of the long period, which is
the sum of the thickness of the crystalline lamellae and amorphous layers, for the
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Figure 4.36 Characteristic SAXS correlation function obtained for the pure dry PEO-PU
polymer; polymer saturated with 6.6% acetaminophen and saturated with 6.4% caffeine.
The parameter Lp defines the long period (the sum of the thickness of the crystalline
lamellae and amorphous layer).[155]

a

b

Figure 4.37 POM images of 10%APAP-PEO at Tx of (a) 30 oC and (b) 50 oC.
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chlorpropamide(CPM)/PEG(MW 3350) solid dispersion system as compared to pure
PEG.[222] As can be seen in Figure 4.38, the diffraction peak in the SAXS profile of
20%CPM/PEG shifted to a smaller scattering vector, which corresponded to a larger long
period of 11.8nm. The long period of once-folded pure PEG was 11.0 nm. The diffraction
peak shifted even further to a smaller scattering vector for the 40%CPM/PEG, where the
long period increased to approximately 14 nm. TEM images also indicated more
extensive amorphous regions between lamellae of PEO N10 after ketoprofen was meltmixed into the matrix.[223] In Figure 4.39, the darker stained bands indicate the
amorphous phase between crystallites. Although the morphology of the two types of
samples resemble each other, the amorphous region of ketoprofen/PEO that lie between
the crystalline regions are wider, suggesting that ketoprofen in the dispersion resides in
the amorphous region.
It is important to determine APAP’s location in the crystalline portion of PEO
since the drug diffusion can be hindered due to the presence of crystallites.[85] The deeper
APAP is buried in the PEO chains, the harder it is for APAP to be released during
dissolution. Future work to determine the location and physical state of the APAP
(amorphous or crystalline) and its physical size following the PEO chain folding will be
very interesting. Unfortunately, the author’s efforts to locate a SAXS have failed. As a
result, this part of the work will be continued in 2012. Nevertheless, the number of
spherulitic nuclei determined from the POM experiments is a good indication of drugpolymer miscibility. At 30 oC, the APAP’s solubility in PEO is about 1% because the
number of nuclei is the same for pure PEO, 0.1%APAP-PEO and 1%APAP-PEO. Based
on the same criteria, the solubility at 50 oC is about 10%. Previous experimental work
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concluded that the solubility at room temperature was less than 10% by using various
characterization techniques such as SEM, XRD, DSC and DMTA. As compared to those
techniques, the POM method has its advantage of being efficient because there is no need
to wait for APAP’s recrystallization from PEO, a phenomenon that could take days if not
months to be detectable especially for samples with low APAP concentration. This is a
simple and straight-forward way to estimate a drug’s solubility in a semi-crystalline
polymer at temperatures below the polymer’s melting point.

Figure 4.38 SAXS of different compositions of CPM/ PEG dispersions crystallized at
different temperatures.[222]

113

Figure 4.39 TEM micrographs of melt-processed neat PEO (right) and melt-processed
20%ketoprofen/PEO blend (left).[223]

To study the spherulitic growth kinetics, more spherulitic growth rates were
measured and plotted in Figure 4.40. The Hoffman-Lauritzen (HL) theory was applied by
utilizing Equation (4.13) and results were plotted in Figure 4.41. Only one regime of
crystal growth is observed for each sample. Cheng et al. reported that for pure PEO
regime III takes place for degrees of supercooling larger than 17.5 K, and regime II takes
place for supercoolings between 10 and 17.5 K (Figure 4.42).[92] Regime I growth
appears to be confined to a very narrow range of ∆T between 8.5 and 10 K. The
supercooling ranges used here are 16.1 K < ∆T < 22.1 K for pure PEO, 19.3 K < ∆T <
25.3 K for 2%APAP-PEO, 23 K < ∆T < 29 K for 10%APAP-PEO, and 32.1 K < ∆T <
38.1 K for 20%APAP-PEO. The supercooling ranges for all samples are close to or larger
than 17.5K, meaning that both PEO and APAP-PEO mixtures behave a regime III crystal
growth.
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Figure 4.40 Isothermal spherulitic growth rate G (µm/s) vs. crystallization temperature
(Tx, ºC) for PEO (◊), 2%APAP-PEO (□), 10%APAP-PEO (Δ) and 20%APAP-PEO (×).
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Figure 4.41 Hoffman-Lauritzen (HL) plots for PEO (◊), 2%APAP-PEO (□), 10%APAPPEO (Δ) and 20%APAP-PEO (×) blends.
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Kg is the slope of the linear HL function in Figure 4.41 and the obtained values for
APAP-PEO systems are listed in Table 4.5. The nucleation constant Kg increases with
APAP concentration, with 2%APAP-PEO being 1.6 times, 10%APAP-PEO being 3
times, and 20%APAP-PEO being 5.6 times of pure PEO. Using the stem width a0 =
0.462 nm, and ∆Hf = 2.13 × 109 erg/cm3 as previously determined by Godovsky et
al.,[224] the products of lateral and folding surface free energies σσe are calculated based
on Equation (4.12). The lateral surface free energy σ is estimated by the Thomas-Stavely
relationship[225] and it is σ = 0.1a0(∆Hf) = 9.8 erg/cm2. The folding surface free energy σe
as well as the work of chain folding q = 2 σeA,[181] where A is the molecular crosssectional area and is 0.214 nm2 for PEO, are then calculated and listed in Table 4.5. The
σe value for pure PEO is in good agreement with the σe being 26-28 erg/cm2 of PEO in
regime III reported by Cheng.[92] Cheng et al. have observed that the folding surface free
energy σe of phenoxy-end-capped PEO is about 1.3 times higher than that of PEO,[91] and
Huang et al. have found the σe of single C60(fullerene)-capped PEO is of about 1.8 times
larger than that of PEO, while that of double C60-capped PEO is about 2.5 times larger
than that of PEO.[197] In this study, the σe values of 2%, 10% and 20%APAP-PEO are
about 1.6 times, 2.9 times and 5.4 times those of pure PEO, respectively, indicating
strongly that chain folding is much more difficult after APAP is incorporated into PEO.
Since the APAP “defects” are either excluded or included in the PEO crystals, it is
reasonable that extra work for chain folding is needed.
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Figure 4.42 Hoffman-Lauritzen (HL) plots for PEO crystallized from the melt. From top
to bottom, MW = ■ 23,000, ▲ 56,000, ● 105,000.[92]
Table 4.5 Kinetic Data of PEO and APAP-PEO Blends from POM Study
Sample

Kg (III)(104 K-2)

σσe (erg2/cm4)

σe (erg/cm2)

q (kJ/mol)

PEO

5.9

278

28.2

7.3

2%APAP-PEO

9.4

435

44.2

11.4

10%APAP-PEO

17.8

818

83.1

21.4

20%APAP-PEO

33.1

1499

152.3

39.2

4.5.4 Macroscopic Properties – Differential Scanning Calorimetry (DSC)
An example of the isothermal DSC curves at various crystallization temperatures is
presented in Figure 4.43. The Avrami parameter n values and the overall crystallization
rate constants Kn are obtained from the double logarithmic plots of Equation (4.15). The
log[-ln(1-X(t))] versus log t plots are shown in Figure 4.44. The Avrami exponents n for
PEO, 2%APAP, 10%APAP and 20%APAP-PEO are 2.0, 2.2, 2.1 and 1.7, respectively.
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Figure 4.44 Avrami analysis of 10%APAP-PEO crystallized at various Tcs.
Since no systematic variation of n with composition or temperature is found, the
crystal growth control mechanism is very likely to be the same for all samples. Based on
Schultz’s summary results in Table 4.4,[203, 204] n = 1.5 demonstrates spherulitic growth of
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heterogeneous nucleation, with the rate limiting step being diffusion of polymer
molecules to or from the growth surface.
The overall crystallization rate constant Kn is a combination of linear growth rate
and nucleation density (rate). When the nucleation is instantaneous, the linear growth rate
G is related to Kn by the simple relation G

∝K

1/n
n ,

as shown in the early work of

Mandelkern, where n is the Avrami exponent.[226] Rewriting Equation (4.13), one gets the
following relationship:
Kg
1
U*
ln K n − ln( ∆T ) +
= ln A0 −
n
R (Tc − T∞ )
fTc ∆T

(4.17)

Kn and n, calculated from Avrami analysis, are used in the plot of Figure 4.45
based on Equation (4.17). Since all supercooling ∆Ts are larger than 17 K as shown
earlier, regime III is used to analyze the kinetic data. Table 4.6 lists the values of Kg,
folding surface free energies σe, and the work of chain folding q. The values are in good
agreement from those obtained from the POM study. σe and q for the 2, 10% and
20%APAP-PEO are 1,4, 3.3 and 6.1 times that of pure PEO, respectively. In summary,
incorporation of APAP makes the PEO chains behave in a “stiffer” fashion and makes it
more difficult to fold in the process of crystallization.
The efficiency of nucleating agents is usually estimated from the changes of the
crystallization temperature (Tcp) by cooling a polymer sample from the melt. Upon
cooling, the sample will crystallize at a given temperature, and an effective nucleating
agent will cause Tcp of the homopolymer to increase, with a higher temperature
corresponding to an increased level of nucleation.[227-230] Figure 4.46 shows the Tcp of
isotactic

polypropylene

(iPP)

doped

with

three

different

nucleating

agents,

poly(vinylcyclohexane) (PVCH), 1,2,3,4-bis(3,4-dimethyl-benzidilene sorbitol (M 3988),
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analysis of isothermal DSC.

Table 4.6 Kinetic Data of PEO and APAP-PEO Blends from DSC Study
Sample

Kg (III)(104 K-2)

σσe (erg2/cm4)

σe (erg/cm2)

q (kJ/mol)

PEO

5.1

240

24.3

6.3

2%APAP-PEO

7.0

325

33.1

8.5

10%APAP-PEO

17.3

796

80.9

20.9

20%APAP-PEO

32.4

1467

149.1

38.4

Figure 4.46 Comparison of the efficiency of the three nucleating agents. Effect of
nucleating agent content on the peak temperature of crystallization of iPP. (○) PVCH, (□)
M 3988, (Δ) NA21 E.[227]
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and a traditional commercial nucleating agent NA21 E.[227] It is seen that all three agents
can increase the Tcp and promote the nucleation of iPP. At a nucleating agent
concentration of 200 ppm, the nucleating effect increases in the following order of M
3988 < NA21 E < PVCH judging from Tcp increase. The Tcp increase resulting from 200
ppm of M 3988 is only 3 oC while for the other two nucleating agents it is more
pronounced and is around 13 oC and 20 oC. Thus, it is not surprising to see in their POM
results, Figure 4.47, that M 3988 is a poor nucleating agent allowing for the few
nucleated spherulites to grow to large sizes, which would render the i-PP opticality, not
clear and more brittle than the i-PP nucleated by the other two agents.

Figure 4.47 Structure development in the presence of 200 ppm of the three nucleating
agents studied. Polarized microscope images taken at Tc = 130 oC on quenched samples;
(a) M3988, (b) NA21E, (c) PVCH.[227]
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The Tcps and enthalpies of PEO containing different APAP concentration are
plotted in Figure 4.48. The Tcps are basically the same for PEO and low APAP
concentration samples, which are 41.1, 41.4, 41.4 and 41.5 oC for PEO, 0.1%, 1% and
2%APAP-PEO, respectively. The Tcps of 10% and 20%APAP-PEO samples, however,
are 36.9 and 33.7 oC, respectively, substantially lower. Additionally, the crystallization
enthalpy is reduced from 147.2 J/g for pure PEO to 134.8, 127.4 and 117.2 J/g for 0.1%,
10% and 20%APAP-PEO, respectively. The results show that APAP decreases the
nucleation efficiency and inhibits the crystallization of PEO, which is consistent with
previous kinetic result conclusions that the fold surface free energy σe is increased and the
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Figure 4.48 The crystallization temperature (Tcp) and enthalpy (∆Hc) during nonisothermal cooling cycle at 10 oC/minute.

CHAPTER 5
CONTRIBUTIONS, CONCLUSIONS AND PROPOSED FUTURE WORK

The main objective and contribution of the thesis was to explore and develop novel and
rather straight-forward experimental techniques for determining the solubility of APIs in
polymer excipients at both hot-melt mixing processing temperatures, where the API solid
dispersions/solutions are formed, and at ambient temperature, where the resulting oral
dosages are stored and used. Knowledge of the increased temperature solubility, as well
as the degree to which the API/excipient solid dispersion is able to remain this high
solubility stably over its shelf life, is of paramount importance in understanding the
emerging field of pharmaceutical hot-melt mixing/extrusion. Thus, developing novel and
straight-forward solubility characterization methods at both processing and ambient
temperatures, which are appropriate for such temperature sensitive material systems and
which borrow techniques from the field of polymer rheology and thermomechanical
properties characterization, have the potential of advancing this field more rapidly.
Solid dispersions of a model drug, acetaminophen (APAP), and a pharmaceutical
grade polymer excipient poly(ethylene oxide) (PEO) of Mw= 100,000 g/mol, were
prepared by hot-melt mixing. The main reason for choosing PEO, which is semicrystalline (80% crystallinity), instead of a totally amorphous polymer excipient was to
have the opportunity to explore the ambient temperature solubility of APAP in both the
crystalline and amorphous phases of PEO.
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5.1 Contributions
A novel rheological method measuring the viscosity of drug-polymer melts of different
API concentrations at temperatures above the polymer’s melting point or glass transition
temperature, but below the drug’s melting point has been developed to determine the
drug’s solubility in the polymer. Below that solubility limit, the viscosity of the molten
mixture will decrease with increasing drug concentration denoting the plasticizing effect
of the API. Above the solubility limit, the viscosity will increase with increasing drug
concentration denoting the formation of a suspension created by API particles, which are
able to dissolve at that temperature. Thus, the drug concentration corresponding to the
minimum viscosity is the solubility at the specific temperature. The method is powerful,
using accurate rheometers which do not expose the polymer excipient to high temperature
for long time, is conducted under N2, and which, therefore, can be applied to investigate
many temperature sensitive drug-polymer systems. Furthermore, very few assumptions
are made in the experimental study and results analysis. The solubility data determined
rheologically can be used to optimize the HME processing temperature “window” in
order to achieve a fully miscible drug-polymer system with the minimum risk of
degradation.
As mentioned above, a semi-crystalline polymer was used as the excipient in this
thesis work. Such a polymer allows for the use of polarized optical microscopy to study
the polymer/drug spherulitic nucleation and growth rates, and morphology. As an
example, the number of spherulitic nuclei can be used to determine a drug’s solubility in
the polymer at temperatures below the polymer’s melting point, e.g., ambient
temperature. When the drug concentration is below the solubility limit, the “quality” of
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the spherulites will deteriorate with increasing drug concentration. Above the solubility
limit, the number of spherulitic nuclei will increase dramatically with increasing drug
concentration, due to the fact that the supercooled API acts as a nucleating agent. The
method only requires a hot-stage polarized microscope, and thus it is easily accessible
and straight-forward. It is the first method that can determine a drug’s solubility in a
semi-crystalline polymer accurately. As compared to other characterization techniques
such as SEM, XRD, DSC and DMTA, the POM method has its advantage of being
efficient because there is no need to wait for drug’s recrystallization from the semicrystalline polymer, a phenomenon that could take days if not months to be detectable
especially for samples with low drug concentration.

5.2 Conclusions
Processing HMM conditions were optimized and fixed in order to focus the study on
material properties. Rheological, microscopic and thermal methods were used to measure
APAP’s solubility in PEO at both hot-melt extrusion or hot-melt mixing processing
temperatures and storage temperature. As mentioned above, the strain-controlled
rheometer measured the viscosity of APAP-PEO and the solubility data were obtained
from the critical point on the curve of viscosity vs. drug loading. The solubility of APAP
in PEO was also obtained from measuring the glass transition temperature at different
drug loadings. Results from the two methods agree with each other and are further
confirmed by hot-stage optical microscopic observation. The Tmmix/Tm(PEO) diagram
developed in this work, which is essentially a “phase diagram”, can be used to determine
the optimal range of HME or HMM processing conditions and mixture composition.
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The apparent drug solubility at room temperature was estimated through Tg
measurements using DSC and DMTA, SEM observations, and XRD analysis. The
APAP-PEO system was found to be a very difficult system because the miscibility of the
two components is very poor at room temperature even though the components can
achieve a fully miscible molten polymeric state at processing temperatures. One major
reason is that PEO is a semi-crystalline polymer with a high tendency to recrystallize
once the temperature drops below its melting point (62 oC). The apparent drug solubility
after a month’s storage was estimated to be between 5-10%. All samples with APAP
concentration ≥ 10% showed extensive APAP recrystallization. For 20% and 30%APAPPEO, APAP recrystallized almost instantaneously upon cooling to room temperature and
the recrystallization process slowed down to an undetectable rate after one day. For the
10%APAP-PEO system, the recrystallization process was found to be slower. However,
the size and shape of the APAP crystalline particles formed by recrystallization were
independent of the drug loading and did not change with increasing storage time. APAP’s
recrystallization was found to be sensitive to the presence of the nanoclays melt-mixed
into the APAP-PEO system during HMM. XRD spectra showed that nanoclays facilitated
APAP’s recrystallization.
A model using Flory-Huggins lattice theory and thermodynamic mixture phase
equilibria was utilized to predict APAP’s solubility in PEO. The interaction parameter χ
was calculated to be -1.65 from the depression of drug’s melting point determined from
the Tmmix/Tm(PEO) diagram. The drug’s solubility in amorphous PEO was estimated to be
11.7% at 300 K. Since PEO is a semi-crystalline polymer with crystallinity of 80%, the
actual solubility is around 2.3%, assuming no APAP molecules dissolve in the crystalline
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part of PEO. The solubility of APAP in PEG 400 was calculated to be 14.6% by using the
same χ of -1.65, while the experimental measurement was 17.1%. The good match
between the experimental and calculated data suggests that the χ for APAP-PEO
calculated from the melting point depression method is a reasonable estimate.
The nucleation and crystallization behavior of PEO was altered by the
incorporation of APAP. At high crystallization temperature (50

o

C), pure PEO,

0.1%APAP-PEO, 1%APAP-PEO and 10%APAP-PEO had the same low number of
spherulitic nuclei, indicating that APAP and PEO were fully miscible for all the
compositions. At low crystallization temperature (30 oC), the number of nuclei for
10%APAP-PEO was dramatically higher, suggesting that APAP was oversaturated and,
therefore, recrystallized and acted as a nucleating agent. The fact that 1%APAP-PEO had
more nuclei than PEO did at 40 oC hinted that the solubility was less than 1%. The reason
for 1%APAP-PEO to have the same amount of nuclei as PEO at 30 oC was attributed to
the low molecular mobility at that temperature so that APAP did not recrystallize even
though the solubility limit was exceeded. Based on the results, amorphous APAP could
exist in the crystalline portion of PEO, possibly between the concentration of 0.1 and 1%
at 30 oC.
The impact of the interaction parameter and the polymer MW on the Gibbs free
energy of mixing ΔGm was investigated. The χ, which is controlled by the drug-polymer
interaction, was found to play an important role while the polymer MW showed
negligible effect on ΔGm. The drug’s solubility could be altered noticeably by the change
of both χ and MW. The study also suggests that the depression of drug’s melting point is
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a good indicator for preliminary polymer screening. The polymer that reduces the melting
point the most, is likely to be most miscible with the drug.
The releasing rate of APAP was slowed down significantly after melt-mixing with
PEO. Nanoclay-containing samples presented much slower dissolution rates compared to
both the drug powder and melt-mixed APAP-PEO. Data analysis of the dissolution
results suggests that the drug’s release mechanism changes from an erosion dominant
mode to a diffusion dominant one, due to the addition of nanoclays. The results suggest
that nanoclays may be utilized to tailor the drug’s releasing rate.
The crystallization behavior of pure PEO and APAP-PEO mixtures was studied
by using polarized optical microscopy, isothermal DSC and nonisothermal DSC. Solvent
evaporation method was utilized to prepare clean APAP-PEO and PEO films. The
equilibrium melting temperature Tm0 was found to increase with APAP concentration by
using the Hoffman-Weeks equation. At high crystallization temperature (50 oC), the
Maltese cross pattern and symmetry of the PEO spherulites were disrupted in the
presence of 10%APAP. At low crystallization temperature (30 oC), 10%APAP-PEO had
significantly more spherulitic nuclei as compared to pure PEO, 0.1%APAP-PEO and
1%APAP-PEO. The morphological, spherulitic growth and number of spherulitic nuclei
analysis appears to be a promising, simple and novel method to determine a drug’s
solubility in a semi-crystalline polymer at temperatures below polymer’s melting point
and close to ambient.
An extensive spherulitic nucleation and growth kinetics study using the classical
theoretical relationships, e.g., the Hoffman-Lauritzen (HL) and Avrami theories, was
conducted. The spherulitic growth rates G of PEO were suppressed with increasing
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APAP concentration. HL theory was used to calculate the kinetic parameters. Both POM
and DSC analysis yielded similar values for the nucleation constant Kg as well as the fold
surface free energy σe and work of chain folding q. The values of σe and q increased with
APAP concentration, indicating that the chain folding of PEO became much more
difficult because of hindering by APAP. Non-isothermal DSC showed that APAP
reduced the nucleation efficiency and inhibited the crystallization of PEO, which is
consistent with the kinetic results that the chain folding of PEO became more difficult
with increasing APAP concentration.

5.1 Proposed Future Work
The spherulitic nucleation and growth kinetics study suggests that APAP is mostly likely
working as a chemical defect and is either rejected from or included in the PEO crystals
during chain folding. However, the physical state (amorphous, crystalline) and the size of
the APAP are unknown due to the detection limit of the instruments for the crystallization
study. SAXS, TEM and micro-IR spectroscopy coupled with POM can be utilized in the
future to analyze the location of the APAP in PEO spherulites, namely interspherulitic,
interfibrillar, interlamellar or intralamellar. By determining the location of APAP, it is
thereby possible to estimate the size, physical state and role of APAP.
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